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Protein	   phosphatase	   2A	   (PP2A)	   holoenzymes	   are	   present	   in	   most	   cell	   types,	   including	  cardiac	  myocytes,	  where	  they	  provide	  a	  large	  proportion	  of	  serine	  (Ser,	  S)	  and	  threonine	  (Thr,	   T)	   phosphatase	   activity.	   PP2A	   family	   members	   comprise	   a	   catalytic	   C	   subunit,	   a	  scaffold	  A	  subunit	  and	  a	  B-­‐type	  subunit,	  which	   regulates	   subcellular	   targeting,	   substrate	  specificity	  and	  catalytic	  activity.	  Previous	  studies	   in	  our	   laboratory	  showed	   that	   in	  adult	  rat	   ventricular	   myocytes	   (ARVM)	   the	   subcellular	   localization	   of	   the	   regulatory	   B56α	  subunit	   is	  altered	   in	  response	  to	   isoprenaline	  (ISO)	  stimulation.	  This	  encouraged	  further	  studies	  of	  B56	  subunits	  in	  β-­‐adrenergic	  regulation	  of	  cardiac	  PP2A,	  which	  form	  the	  basis	  of	  this	  PhD	  project.	  	  
Immunoblot	  analysis	  of	  ARVM	  samples	  revealed	  that	  in	  this	  cell	  system	  regulatory	  B56α,	  -­‐γ	  and	  -­‐δ	  subunits	  are	  expressed	  at	  protein	  level.	  Protein	  expression	  of	  PP2A	  scaffold	  and	  catalytic	   subunits	   was	   also	   confirmed.	   The	   subcellular	   distribution	   and	   ISO-­‐induced	  translocation	   of	   PP2A	   subunits	   was	   investigated	   by	   fractionation	   of	   ARVM.	   B56α	   was	  depleted	   from	   the	   myofilament/nuclear	   compartment	   and	   was	   enriched	   in	   the	  cytosolic/membrane	   compartment	   of	   ISO-­‐stimulated	   myocytes.	   This	   was	   observed	   also	  for	  PP2A	  scaffold	  and	  catalytic	  subunits.	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1.2 β-­‐Adrenergic	  regulation	  of	  cardiac	  protein	  phosphorylation	  1.2.1 Cardiac	  adrenergic	  receptor	  signaling	  Adrenaline	   and	   noradrenaline	   regulate	   cardiac	   function	   through	   stimulation	   of	   ARs.	  Cardiac	   ARs,	   which	   include	   α-­‐ARs	   (α1A,	   α1B	   and	   α1D)	   and	   β-­‐ARs	   (β1,	   β2	   and	   β3),	   are	   G	  protein-­‐coupled	   receptors	   (GPCRs)	   and	   as	   such,	   signal	   via	   heterotrimeric	   G	   proteins.5-­‐7	  The	  Gα	  subunit	  binds	  guanosine	  diphosphate	  (GDP)	  or	  guanosine	  triphosphate	  (GTP)	  and	  GPCR	  stimulation	  promotes	  G	  protein	  activation	  by	  inducing	  the	  exchange	  of	  GDP	  for	  GTP.	  The	   Gα	   and	   Gβγ	   subunits	   dissociate	   and	   signal	   to	   distinct	   effector	   proteins,	   including	  enzymes	   and	   ion	   channels.	   The	   hydrolysis	   of	   GTP	   to	   GDP	   is	   mediated	   by	   the	   GTPase	  activity	   of	   the	   Gα	   subunit	   and	   promotes	   reformation	   of	   the	   G	   protein	   complex.6,8	   The	  responses	   induced	   by	   GPCR	   stimulation	   depend	   on	   the	   effector	   protein(s)	   activated	  downstream	   of	   the	   receptor.	   This	   in	   turn	   largely	   depends	   on	   the	   type	   of	   Gα	   subunit	  comprised	   in	   the	  coupled	  G	  protein.	  As	  an	  example,	  β-­‐ARs	  couple	   to	  Gαs	  and	  Gαi	  proteins	  and	   the	   receptors	   thus	   signal	   via	   PKA.	   In	   contrast,	   α-­‐ARs	   couple	   to	   Gαq	   proteins	   and	  therefore	  signal	  via	  protein	  kinase	  C	  (PKC).6,8	  	  
In	  the	  physiological	  mammalian	  heart	  β-­‐ARs	  represent	  the	  largest	  population	  of	  ARs.	  The	  β1	  and	  β2	  subtypes,	  which	  are	  most	  abundant,	  are	  expressed	  at	  a	  ratio	  of	  ~80:20	  and	  their	  stimulation	   gives	   rise	   to	   the	   positive	   inotropic,	   chronotropic	   and	   lusitropic	   effects	   of	  adrenergic	  stimuli	  (i.e.	  adrenaline	  and	  noradrenaline).5-­‐7	  Both	  β1-­‐	  and	  β2-­‐ARs	  couple	  to	  Gαs	  (stimulatory)	  proteins	  and	   their	  activation	   leads	   to	   the	  accumulation	  of	  cyclic	  adenosine	  3′,5′-­‐monophosphate	   (cAMP)	   and	   activation	   of	   PKA,	   via	   stimulation	   of	   adenylyl	   cyclase	  (Figure	  1.2).9	  As	  described	  in	  more	  detail	   in	  subsequent	  sections,	  this	  signaling	  pathway,	  referred	   to	   as	   the	   classical	   β-­‐AR	   signaling	   pathway,	   is	   critical	   in	   the	   regulation	   of	  cardiomyocyte	  contractility	  (acute	  effects)	  and	  can	  induce	  cardiac	  hypertrophy	  and	  failure	  (chronic	  effects).10	  	  








phosphorylating	  target	  proteins	  on	  Ser	  and	  Thr	  residues.11-­‐13	  The	  subcellular	  targeting	  of	  PKA	  holoenzymes	  is	  mediated	  by	  A-­‐kinase	  anchoring	  proteins	  (AKAPs),	  which	  contribute	  to	  PKA	  signaling	  specificity	  by	  colocalizing	   the	  kinase	  with	  enzymes	  that	  counterbalance	  its	  activation	  and	  its	  effects.14,15	  Phosphodiesterases	  (PDEs)	  regulate	  PKA	  activation	  (and	  protein	   phosphorylation)	   by	   degrading	   cyclic	   nucleotide	   second	   messengers,	   including	  cAMP.	  Furthermore,	  they	  compartmentalize	  cAMP	  signals	  such	  that	  selected	  pools	  of	  PKA	  are	  activated	  in	  response	  to	  a	  given	  stimulus.16-­‐21	  Protein	  phosphatases,	  which	  can	  also	  be	  found	  in	  AKAP	  complexes,22	  oppose	  the	  effects	  of	  PKA	  by	  reversing	  phosphorylations.	  	  
Although	  PKA	   is	   considered	   to	  be	   the	  main	  effector	  of	   cAMP,	   the	   second	  messenger	   can	  elicit	   effects	   that	   are	   independent	   of	   PKA.	   For	   example,	   cAMP	   directly	   regulates	  hyperpolarization-­‐activated	  cyclic	  nucleotide-­‐gated	  channels23	  and	  PDEs.24	  Another	  target	  (and	  effector)	  of	  cAMP	  is	  Epac,	  a	  guanine	  nucleotide	  exchange	  protein	  directly	  activated	  by	  cAMP.25	  Epac	  is	  expressed	  in	  the	  heart	  and	  the	  affinity	  of	  cAMP	  for	  Epac	  is	  comparable	  to	  the	  affinity	  for	  PKA.26	  Although	  the	  cardiac	  effects	  of	  Epac	  are	  less	  well	  characterized	  than	  the	  effects	  of	  PKA,	  evidence	  suggests	   that	  Epac	  activity	   impacts	  on	   intracellular	   calcium,	  affecting	  contractility.27	  It	  has	  been	  shown	  that	  in	  adult	  ventricular	  myocytes	  Epac	  induces	  calcium	   release	   from	   the	   sarcoplasmic	   reticulum	   (SR)	   in	   a	   signaling	   pathway	   that	  sequentially	  involves	  phospholipase	  Cε,	  PKCε	  and	  calcium/calmodulin	  kinase	  (CaMK)	  II.28	  Epac	   may	   also	   play	   a	   role	   in	   gene	   transcription	   and	   cardiac	   hypertrophy	   and	   in	   adult	  myocytes,	  where	  it	  induces	  a	  perinuclear	  increase	  in	  calcium,	  its	  sustained	  activation	  leads	  to	  the	  nuclear	  export	  of	  histone	  deacetylase	  (HDAC)	  5.29	  	  








The	   function	   of	   β-­‐ARs	   is	   subject	   to	   post-­‐translational	   regulation,	   primarily	   by	  phosphorylation.	   This	   is	   accomplished	   by	   GPCR	   kinases	   (GRKs,	   also	   known	   as	   β-­‐AR	  kinases)	   and	   PKA,	   which	   phosphorylate	   the	   receptors	   at	   sites	   in	   their	   intracellular	  domains.35	  The	  phosphorylation	  of	  β-­‐ARs	  by	  GRKs	  leads	  to	  the	  recruitment	  of	  β-­‐arrestins.	  By	  binding	  to	   the	  receptors,	   these	   impede	   its	   interaction	  with	  the	  G	  protein	  and	  thereby	  avoid	   the	   potentially	   harmful	   effects	   of	   chronic	   receptor	   activation.36	   β-­‐Arrestins	   can	  induce	   G	   protein-­‐independent	   signaling	   pathways,	   which	   include	   cytoprotective	  pathways.37	  β-­‐Arrestin,	  recruited	  to	  β1-­‐ARs	  via	  GRK5/6,	  can	  transactivate	  the	  extracellular	  growth	  factor	  receptor,	  for	  example.38	  This	  receptor	  then	  activates	  pro-­‐survival	  signaling	  pathways	   involving	   extracellular	   signal-­‐regulated	   kinase	   (ERK)	   and	   Akt,	   protecting	   the	  heart	  against	  sustained	  β1-­‐ARs	  stimulation.38	  
Alternative	  signaling	  pathways	  can	  also	  occur	  downstream	  of	  β2-­‐ARs,	  which	  additionally	  couple	   to	  Gαi	   (inhibitory)	  proteins.	  The	  consequences	  of	  β2-­‐AR	  stimulation,	   including	   the	  effects	   on	   contractility,	   are	   species-­‐dependent	   and	   age-­‐dependent	   and	   are	   different	   in	  physiological	   and	  pathological	  hearts.39-­‐41	  Whilst	   the	  Gαi	   subunit	   fine-­‐tunes	   cAMP	  signals	  by	   inhibiting	   the	   activity	   of	   adenylyl	   cyclase,	   its	   counterpart	   Gβγ	   subunit	   can	   induce	  parallel	  signaling	  pathways.40	  For	  example,	  the	  anti-­‐apoptotic	  effects	  of	  β2-­‐AR	  stimulation	  arise	  from	  activation	  of	  phosphoinositide	  3-­‐kinase	  (PI3K)	  and	  Akt.42	  The	  induction	  of	  this	  signaling	  pathway	  is	  believed	  to	  protect	  cardiac	  myocytes	  from	  apoptosis,	  induced	  by	  the	  parallel	  Gαs	  pathway	  downstream	  of	  β1-­‐ARs.42	  	  








sarcolemmal	   sodium	   gradient	   and	   thereby	   facilitates	   the	   extrusion	   of	   calcium	   via	   the	  sodium/calcium	   exchanger.46	   Phosphorylation	   of	   the	   myofilament	   proteins	   troponin	   I	  (cTnI)	  at	  S23	  and	  S2447	  and	  myosin	  binding	  protein-­‐C	  (cMyBP-­‐C)	  at	  S273,	  S282	  and	  S30248	  promotes	   earlier	   onset	   of	   relaxation	   (by	   reducing	  myofilament	   calcium	   sensitivity)	   and	  force	   generation	   (by	   accelerating	   actin-­‐myosin	   cross-­‐bridge	   cycling).	   As	   previously	  mentioned,	  CaMKII	  additionally	  phosphorylates	  the	  RyR2	  at	  S2814	  and	  PLB	  at	  T17.	  Some	  of	   the	  proteins	   that	   regulate	  ECC,	  PLB	  being	  one	  example,	   can	  also	  be	   regulated	  by	  PKA	  indirectly,	  via	  inhibitor-­‐1	  (I-­‐1)	  of	  protein	  phosphatase	  1	  (PP1).	  The	  phosphorylation	  of	  I-­‐1	  at	   T35	   increases	   its	   inhibitory	   activity	   towards	  PP1.	  By	   reducing	  PP1	   activity,	   substrate	  phosphorylation	  is	  amplified.49	  	  
1.2.3 Role	  in	  the	  regulation	  of	  gene	  and	  protein	  expression	  The	   stimulation	   of	   β-­‐ARs	   can	   induce	   long-­‐term	   changes	   by	   modulating	   gene/protein	  expression.	  PKA	  can	  induce	  gene	  expression	  via	  cAMP	  response	  element	  binding	  protein	  (CREB).50	  PKA	  phosphorylates	  the	  transcription	  factor	  at	  S133	  and	  thereby	  stimulates	  the	  expression	   of	   genes	   that	   feature	   a	   cAMP	   response	   element	   (CRE)	   in	   their	   promoter	  region.50	  For	  example,	  the	  β2-­‐AR	  gene	  promoter	  includes	  a	  CRE	  and	  expression	  of	  the	  β2-­‐AR	  increases	  in	  response	  to	  receptor-­‐mediated	  increase	  in	  cAMP.51	  HDACs,	  which	  repress	  the	  expression	  of	   fetal	   cardiac	  genes	   (and	  hypertrophy)	  by	   inhibiting	  myocyte	  enhancer	  factor	  2	  (MEF2),52	  are	  another	  important	  class	  of	  nuclear	  proteins	  regulated	  in	  response	  to	  β-­‐adrenergic	   stimulation.	   Studies	   suggest	   that	   acute	   stimulation	   of	   β-­‐ARs	   promotes	  nuclear	   retention	   of	   HDAC453	   and	   HDAC554	   by	   PKA-­‐dependent	   cleavage	   and	   PKA-­‐mediated	   phosphorylation,	   respectively	   and	   thereby	   inhibits	   MEF2	   activity.	   However,	  there	   is	   also	   evidence	   that	   β-­‐AR	   stimulation	   induces	   HDAC5	   nuclear	   export	   and	   MEF2	  activation	  through	  a	  phosphorylation-­‐independent	  manner.55	  	  	  








physiological	   conditions56	   and	   acetyl-­‐CoA	   carboxylase,	   which	   regulates	   fatty	   acid	  synthesis,	   is	   inhibited	   by	   PKA	   through	   phosphorylation.57	   Ultimately,	   by	   inhibiting	   the	  synthetic	   pathway,	   the	   oxidative	   pathway	   can	   proceed.	   Studies	   in	   neonatal	   cardiac	  myocytes	   suggest	   that	   β-­‐AR	   stimulation	   enhances	   insulin-­‐induced	   glucose	   uptake	   and	  regulates	   the	   function	   of	   the	   insulin	   receptor	   in	   signaling	   pathways	   that	   involve	   Akt.58	  Whilst	  short-­‐term	  stimulation	  of	  β-­‐ARs	  facilitates	  glucose	  uptake,	  long-­‐term	  stimulation	  of	  the	  receptors	  leads	  to	  impaired	  insulin	  sensitivity.58	  	  
As	  described	  in	  this	  section,	  it	   is	  clear	  that	  the	  stimulation	  of	  β-­‐ARs	  impacts	  on	  a	  diverse	  range	   of	   cellular	   processes,	   primarily	   through	   activation	   of	   protein	   kinases	   and	   protein	  phosphorylation.	  Although	  PKA	  plays	  a	  dominant	  role,	   the	  effects	  of	  β-­‐AR	  stimuli	  can	  be	  mediated	   by	   other	   protein	   kinases	   (e.g.	   CaMKII,	   ERK,	   Akt	   and	   GRK)	   all	   of	   which	   can	  phosphorylate	   target	   proteins	   on	   Ser	   and	   Thr	   residues.	   Protein	   phosphatases	   reverse	  these	  phosphorylations	  and	  a	  large	  proportion	  of	  the	  cardiac	  Ser/Thr	  phosphatase	  activity	  is	  derived	  from	  PP1	  and	  PP2A.59-­‐61	  	  
	  
	  








1.3 Regulation	  of	  protein	  phosphorylation	  at	  Ser	  and	  Thr	  residues	  1.3.1 Kinases	  versus	  phosphatases	  Protein	  kinases	  represent	  one	  of	  the	  largest	  eukaryotic	  gene	  families.	  In	  humans,	  over	  400	  kinases	  are	  Ser/Thr	  kinases,	   the	  majority	  of	  which	  comprise	  a	  catalytic	  and	  a	  regulatory	  domain	   encoded	   by	   the	   same	   gene.62-­‐64	   The	   number	   of	   catalytic	   subunits	   for	   Ser/Thr	  phosphatases	   (STPs)	   is	   limited	   to	   ~30	   and	   thus,	   STPs	   were	   considered	   non-­‐specific	  enzymes.65-­‐67	   The	   catalytic	   subunit	   of	   most	   STPs	   does	   not	   function	   as	   a	   monomer	   and	  functional	  enzymes	  comprise	  a	  catalytic	   subunit	  associated	  with	  one	  or	  more	  regulatory	  subunits.66	  As	  discussed	  in	  more	  detail	  in	  subsequent	  sections	  of	  this	  general	  introduction,	  the	  diverse	  range	  of	  cellular	  STPs	  thus	  results	  from	  the	  combination	  of	  a	  small	  number	  of	  catalytic	  subunits	  with	  a	  large	  number	  of	  regulatory	  subunits.	  	  
1.3.2 STP	  classification	  In	  the	  initial	  classification	  scheme,	  STPs	  were	  classified	  as	  either	  a	  type-­‐1	  (PP1)	  or	  type-­‐2	  (PP2)	  phosphatase.	  PP1	  dephosphorylated	  the	  β	  subunit	  of	  phosphorylase	  kinase	  and	  was	  inhibited	   by	   I-­‐1	   and	   inhibitor-­‐2	   (I-­‐2).	   PP2	   dephosphorylated	   the	   α	   subunit	   of	  phosphorylase	  kinase	  and	  its	  activity	  was	  not	  sensitive	  to	  either	  inhibitor.	  The	  PP2	  family	  was	  divided	  into	  subtype	  2A,	  2B	  and	  2C;	  PP2B	  was	  calcium	  and	  calmodulin-­‐dependent	  and	  PP2C	  was	  magnesium-­‐dependent.67	  This	  classification	  has	  been	  revised	  and	  STPs	  are	  now	  classified	   into	   three	   families.66	   While	   metal-­‐dependent	   protein	   phosphatases	   and	  aspartate-­‐based	   phosphatases	   represent	   the	   smaller	   families,	   phosphoprotein	  phosphatases	  (PPPs)	  represent	  the	  largest	  family	  and	  include	  PP2A,	  which	  is	  the	  focus	  of	  this	  thesis.	  	  	  
















1.4 Structure	  and	  regulation	  of	  PP2A	  1.4.1 Structure	  of	  PP2A	  PP2A	   is	   ubiquitously	   expressed	   and	   in	   some	   tissues	   accounts	   for	   up	   to	   1%	   of	   the	   total	  cellular	   protein.	   The	   enzyme	   is	   highly	   conserved	   from	   yeast	   to	   humans	   and	   exhibits	  multiple	  functions	  in	  cells.68,69	  PP2A	  is	  a	  tumor	  suppressor	  and	  its	  dysfunction	  in	  cancer	  is	  well	   documented.70-­‐73	   PP2A	   dysfunction	   in	   the	   brain	   underlies	   neurodegenerative	  diseases,	   including	   Alzheimer’s.74,75	   Importantly,	   PP2A	   is	   not	   a	   single	   enzyme	   but	  comprises	   a	   large	   family	   of	   distinct	   holoenzymes	   with	   complex	   mechanisms	   of	  regulation.69,76,77	  	  








1.4.2 Regulation	  of	  PP2A	  
 Regulation	  by	  post-­‐translational	  modification	  of	  the	  core	  enzyme	  1.4.2.1PP2A	   C	   subunits	   are	   regulated	   by	   covalent	   post-­‐translational	   modifications	   at	   the	   C-­‐terminus.	  Amino	  acids	  304	  to	  309	  constitute	  the	  conserved	  “TPDYFL”	  motif	  (T,	  threonine;	  P,	   proline;	  D,	   aspartic	   acid;	   Y,	   tyrosine;	   F,	   phenylalanine;	   L,	   leucine),	  which	   is	   subject	   to	  methylation	   and	   phosphorylation.	   Methylation	   occurs	   on	   the	   free	   carboxyl	   group	   of	  leucine	   309	   and	   is	   regulated	   by	   leucine	   carboxyl	   methyltransferase	   1	   (LCMT-­‐1)	   and	  protein	  phosphatase	  methyl	  esterase	  1	  (PME-­‐1).	  This	  modification	  regulates	  holoenzyme	  formation	  through	  B-­‐type	  subunit	  selection.90-­‐93	  B	  (B55/PR55)	  subunits	  are	  methylation-­‐sensitive	  and	   their	  association	  with	   the	   core	  enzyme	  relies	  on	  C	   subunit	  methylation.	   In	  contrast,	   B’	   (B56/PR61),	   B’’	   (PR72)	   and	   B’’’	   (PR93/PR110)	   subunits	   are	   methylation-­‐insensitive	   and	   associate	  with	   the	   core	   enzyme	   regardless	   of	  methylation.94,95	   C	   subunit	  phosphorylation	   occurs	   on	   Y307.	   In	   vitro	   p60v-­‐src,	   p56lck,	   epidermal	   growth	   factor	  receptor	   and	   insulin	   receptor	   Tyr	   kinases	   phosphorylate	   this	   site.96	   The	   physiological	  kinase(s),	   however,	   are	   unknown.	   Phosphorylation	   on	   Y307	   inactivates	   PP2A.96,97	   As	  suggested	  by	  studies	   in	  vitro	  with	  phospho-­‐mimetic	  mutants	  this	  modification	  might	  also	  inhibit	   the	   recruitment	   of	   selected	   B	   (B55/PR55)	   and	   B’	   (B56/PR61)	   subunits.77,98	  Although	   C	   subunit	   methylation	   and	   phosphorylation	   are	   the	   best-­‐characterized,	   other	  post-­‐translational	  modifications	  have	  been	  reported.	  In	  endothelial	  cells,	  nitration	  of	  Y307	  prevents	  phosphorylation	  of	  the	  site	  and	  increases	  PP2A	  activity.99	  Phosphorylation	  of	  the	  A	   subunit	   was	   also	   recently	   reported	   and	   was	   proposed	   to	   interfere	   with	   C	   subunit	  binding.100	  








details	   remain	   to	   be	   elucidated,	   evidence	   suggests	   that	   I2-­‐PP2A	   inhibits	   the	   enzyme	   by	  binding	  to	  the	  C	  subunit.74	  	  
 Regulation	  by	  associated	  B-­‐type	  subunits	  1.4.2.3B-­‐type	   subunits	   are	   regulatory	   subunits	   that	   determine	   subcellular	   targeting	   and	  substrate	  selectivity.65,105	  The	  classification	  of	  B-­‐type	  subunits	  is	  based	  on	  primary	  amino	  acid	   sequences,	  which	   are	   conserved	   only	   in	  members	   of	   the	   same	   family.	   As	   shown	   in	  Figure	  1.4,	  human	  B-­‐type	  subunits	  are	  encoded	  by	  fifteen	  genes	  and	  the	  products	  of	  these	  genes	   are	   grouped	   into	   four	   families:	   B	   (B55/PR55),	   B’	   (B56/PR61),	   B’’	   (PR72)	   and	  B’’’	  (PR93/PR110).77,87	  Each	  family	  comprises	  between	  three	  and	  five	  isoforms,	  some	  of	  which	  have	  alternative	  splice	  variants.	  Thus,	  B-­‐type	  subunits	  represent	   the	  most	  variable	  PP2A	  subunit	  and	  in	  human	  cells	  at	  least	  96	  holoenzymes	  exist,	  despite	  the	  existence	  of	  only	  two	  catalytic	   subunits.77	   The	   expression	   of	   B-­‐type	   subunits	   is	   spatially	   and	   temporally	  regulated106-­‐108	  such	  that	  selected	  holoenzymes	  can	  exist	  in	  a	  given	  cell	  at	  a	  given	  time.	  The	  targeting	  functions	  of	  B-­‐type	  subunits	  arise	  from	  the	  presence	  (or	  absence)	  of	  localization	  signals.	  For	  example	  B’α,	  B’β	  and	  B’ε	  contain	  nuclear	  export	  signals	  that	   localise	  PP2A	  to	  non-­‐nuclear	   (cytosolic)	   compartments.	   In	   contrast,	   B’γ	   lacks	   this	   sequence	   and	   targets	  PP2A	  to	  nuclear	  compartments.109-­‐111	  B-­‐type	  subunits	   increase	  PP2A	  substrate	  affinity112	  and	   structural	   studies	   of	   Bα-­‐PP2A-­‐mediated	   dephosphorylation	   of	   the	   microtubule-­‐associated	   tau	   protein	   were	   the	   first	   to	   provide	   insight	   on	   how	   this	   might	   occur.113	  Accordingly,	  regulatory	  subunits	  provide	  substrate-­‐docking	  motifs	  that	  facilitate	  the	  initial	  binding	   of	   the	   substrate	   to	   the	   holoenzyme.113	   Furthermore,	   B-­‐type	   subunits	   fine-­‐tune	  PP2A	   catalytic	   activity	   and	   post-­‐translational	   modifications	   of	   selected	   subunits	   can	  enhance	  or	  inhibit	  such	  activity.114,115	  	  
Human	   B’	   subunits,	   henceforth	   referred	   to	   as	   B56	   subunits,	   were	   first	   described	   in	   the	  1990s	  and	   form	   the	  primary	   focus	  of	   this	  project.108,116-­‐118	  As	   shown	   in	  Figure	  1.5,	   these	  subunits	   are	   encoded	   by	   five	   genes	   (PPP2R5A,	   PPP2R5B,	   PPP2R5C,	   PPP2R5D	   and	  








variants	   of	   γ	   and	   δ	   result	   from	   alternative	   gene	   splicing.	   With	   nine	   isoforms,	   the	   B56	  family	  thus	  represents	  the	  largest	  family	  of	  B-­‐type	  subunits.	  	  
 Structure,	  expression	  and	  distribution	  of	  B56	  subunits	  	  	  1.4.2.3.1The	   first	   crystal	   structure	   of	   a	   B56-­‐containing	   PP2A	   holoenzyme	   (B56γ1-­‐PP2A)	   was	  published	  in	  2006.84	  This	  structure	  provided	  insight	  on	  holoenzyme	  formation	  and	  on	  the	  function	  of	  the	  B-­‐type	  subunit.	  A	  surface	  representation	  of	  the	  crystallized	  holoenzyme	  is	  shown	  in	  Figure	  1.6.	  The	  A	  subunit	  adopts	  a	  horseshoe-­‐shaped	  conformation	  and	  interacts	  with	  the	  C	  and	  B-­‐type	  subunits.	  The	  B-­‐type	  subunit,	  which	  shields	  a	  part	  of	  the	  C	  subunit,	  displays	  a	  superhelical	  structure	  that	  comprises	  18	  α	  helices,	  divided	  into	  8	  HEAT	  motifs.	  These	   are	   indicated	   in	   Figure	   1.7.	   Residues	   within	   HEAT2,	   HEAT4	   and	   HEAT5	   interact	  with	   the	   A	   subunit	   and	   residues	   within	   HEAT2,	   HEAT5,	   HEAT6,	   HEAT7	   and	   HEAT8	  interact	  with	  the	  C	  subunit.84	  As	  also	  shown	  in	  Figure	  1.7,	  most	  residues	  are	  conserved	  in	  B56α,	   -­‐β,	   -­‐δ	  and	   -­‐ε	   isoforms,	   suggesting	  a	  common	  mode	  of	   subunit	   interaction	  with	   the	  core	   enzyme.	   In	   the	   crystalized	   holoenzyme,	   a	   concave	   region	   on	   the	   B56	   subunit	   is	  unoccupied;	  this	  region	  comprises	  acidic	  residues	  and	  likely	  serves	  as	  a	  substrate	  docking	  region.84	  These	  structural	  studies	  indicate	  that	  regulatory	  subunits	  modify	  PP2A	  substrate	  selectivity	  by	  altering	  the	  environment	  around	  the	  catalytic	  site	  and	  by	  providing	  contact	  regions	  for	  substrate	  recruitment	  (Figure	  1.8).84	  Whilst	  the	  central	  (core)	  domain	  of	  B56	  subunits	   is	  conserved	  between	  the	   family	  members,	  sequences	  at	   the	  N-­‐terminus	  and	  C-­‐terminus	  are	  different	  and	  determine	  isoform-­‐specific	  functions.	  As	  an	  example,	  in	  cardiac	  cells	   B56α	   localises	   to	   the	   sarcomeric	   M-­‐line.119	   This	   distribution	   is	   determined	   by	   a	  physical	  interaction	  with	  ankyrin-­‐B	  and	  is	  mediated	  by	  13	  amino	  acids	  present	  only	  at	  the	  C-­‐terminus	  of	  B56α.119	  The	  expression	  of	  B56	  subunits	  is	  tissue-­‐specific	  and	  at	  messenger	  RNA	   (mRNA)	   level	  B56α	  and	  B56γ	  are	  most	  abundant	   in	   skeletal	   and	  cardiac	  muscle.	   In	  contrast,	  B56β	  and	  B56δ	  are	  highly	  expressed	  in	  the	  brain.108,116,118,120	  	  








substrate	   affinity,	   activity	   and	   localization	  of	   holoenzymes.	   The	  precise	   consequences	   of	  the	  modification	   depend	   on	   the	   isoform,	   the	   site	   of	   phosphorylation	   and	   cell	   type.	   The	  phosphorylation	   of	   B56γ3	   at	   S510,	   mediated	   by	   ataxia	   telangiectasia	  mutated	   kinase	   in	  response	  to	  DNA	  damage,	  enhances	  the	  stability	  of	  the	  isoform.121	  This	  leads	  to	  increased	  abundance	   of	   B56γ3-­‐PP2A	   complexes	   and	   furthermore,	   increases	   the	   affinity	   of	   this	  holoenzyme	   for	   its	   substrate	   p53.121	   PKA	   and	   PKC,	   activated	   in	   distinct	   signaling	  pathways,	   phosphorylate	   B56δ	   at	   S573114,122	   and	   this	   phosphorylation	   stimulates	   the	  activity	   of	   the	   associated	   catalytic	   subunit.	   In	   contrast,	   the	   phosphorylation	   of	   the	   same	  isoform	  at	  S37	  by	  checkpoint	  kinase	  1	  promotes	  association	  of	  the	  subunit	  with	  the	  PP2A	  core	   enzyme.123	   The	   phosphorylation	   of	   B56α	   at	   S41	   by	   PKC	   inhibits	   the	   activity	   of	   the	  associated	  catalytic	  subunit.115	  In	  contrast,	  its	  phosphorylation	  at	  S28	  by	  protein	  kinase	  R	  promotes	  translocation	  of	  the	  holoenzyme	  from	  the	  nucleus	  to	  mitochondria.124	  Although	  most	   studies	   decribe	   phosphoregulation	   of	   B56	   isoforms,	   a	   recent	   publication	   indicates	  that	  redox	  regulation	  can	  also	  occur.	  Accordingly,	  in	  an	  oxidative	  intracellular	  milieu	  B56δ	  is	   nitrated	   at	   Y289	   and	   this	   interferes	   with	   formation	   of	   B56δ-­‐PP2A.125	   The	   cellular	  mechanisms	  of	  PP2A	  regulation	  are	  summarised	  in	  Figure	  1.9.	  








1.5 PP2A	  holoenzymes	  in	  the	  heart	  A	  common	  approach	  taken	  to	  study	  the	  functions	  of	  PP2A	  in	  cells/tissues	  entails	  the	  use	  of	  naturally	  occurring	  cell-­‐permeant	  phosphatase	  inhibitors.	  The	  most	  widely	  used	  of	  these	  is	   okadaic	   acid	   (OA),	   a	   small	   molecule	   toxin	   produced	   by	   marine	   organisms.126	   OA	  selectively	   inhibits	   PP2A	   at	   lower	   concentrations	   (IC50	   0.1-­‐0.3	   nM)	   and	   additionally	  inhibits	  PP1	  at	  higher	  concentrations	  (IC50	  15-­‐50	  nM).126	  PP2B	  is	  relatively	  insensitive	  to	  this	   inhibitor	  (IC50	  4μM).126	   In	  cells,	  PP2A	  activity	   is	  thus	  the	  phosphatase	  activity	  that	   is	  inhibited	   by	   the	   lower	   concentration	   of	   OA	   and	   PP1	   activity	   is	   comprised	   in	   the	  phosphatase	  activity	  inhibited	  by	  the	  inhibitor	  at	  a	  higher	  concentration.	  Notwithstanding	  the	  unintentional	  inhibition	  of	  PP1	  that	  may	  occur	  in	  the	  cellular	  environment,	  most	  of	  the	  cardiac	  roles	  of	  PP2A	  have	  been	  inferred	  from	  studies	  with	  OA.	  	  
1.5.1 PP2A	  in	  cardiac	  physiology	  
 Role	  in	  the	  regulation	  of	  ECC	  1.5.1.1The	   first	   indication	   that	   protein	   phosphatases	   impact	   on	   cardiac	   ECC	   was	   provided	   by	  Neumann	   et	   al.59	   OA	   mimicked	   the	   effects	   of	   β-­‐AR	   stimulation,	   increasing	   the	   force	   of	  contraction	  and	   the	  rate	  of	   relaxation,	  by	   inhibiting	  PP1	  and	  PP2A59	  and	  PP2A	  has	  since	  been	  implicated	  in	  dephosphorylation	  of	  several	  proteins	  that	  regulate	  ECC.	  De	  Arcangelis	  








when	   PP2A	   is	   displaced	   from	   these	   sites.130	   Therefore,	   these	   studies	   suggest	   that	   PP2A	  regulates	   the	   activity	   of	   LTCCs	   under	   basal	   condition	   and	   in	   response	   to	   β-­‐adrenergic	  stimulation.	  Marx	  et	  al.	  detected	  PP2A	  in	  RyR2	  macromolecular	  complexes	  together	  with	  PP1,	   PKA	   and	   the	   its	   regulatory	   RII	   subunit,	   and	   muscle-­‐specific	   AKAP	   (mAKAP).131	   In	  these	  studies,	  the	  functional	  role	  of	  PP2A	  was	  not	  reported	  and	  the	  possibility	  that	  PP2A	  regulates	  RyR2	  phosphorylation	  (at	  the	  PKA	  or	  CaMKII	  sites)	  remains	  to	  be	  established.	  	  
 Role	  in	  the	  antiadrenergic	  effects	  of	  adenosine	  and	  acetylcholine	  	  1.5.1.2Adenosine	   is	   derived	   from	   adenosine	   triphosphate	   (ATP)	   and	   is	   generated	   in	   the	  extracellular	   environment,	   where	   it	   activates	   purinergic	   receptors.132	   The	   stimulatory	  effects	  of	  catecholamines	  on	  the	  heart	  are	  opposed	  by	  adenosine,	  primarily	  via	  activation	  of	  adenosine	  A1	  receptors.132	  Gupta	  et	  al.	  showed	  that	  ISO-­‐induced	  phosphorylation	  of	  PLB	  was	   reduced	   in	   isolated	   myocytes	   co-­‐stimulated	   with	   N6-­‐phenylisopropyladenosine,	   an	  agonist	  at	  adenosine	  A1	  receptors.133	  Although	  adenosine	  A1	  receptors	  are	  Gαi	  GPCRs,	  this	  response	   was	   independent	   of	   changes	   in	   cAMP	   and	   therefore,	   it	   was	   proposed	   that	  adenosine	   A1	   receptor	   stimulation	   induces	   dephosphorylation	   of	   PLB	   by	   activating	  protein	  phosphatases.133	  Liu	  and	  Hofmann	  studied	  the	  anti-­‐adrenergic	  effects	  of	  adenosine	  further,	   in	   rat	  myocardial	   preparations.134	   In	   isolated	   hearts,	   the	   adenosine	  A1	   receptor	  agonist	  N6-­‐cyclopentyladenosine	  (CPA)	  attenuated	  the	  positive	  inotropic	  effect	  of	  ISO	  and	  this	   effect	   was	   abrogated	   by	   PP2A	   inhibition.134	   Similarly,	   in	   isolated	   myocytes	   CPA	  reduced	  the	  basal	  and	  ISO-­‐induced	  phosphorylation	  of	  PLB	  and	  cTnI,	  and	  this	  effect	  was	  also	  dependent	  on	  the	  activity	  of	  PP2A.134	  Acetylcholine,	  which	  stimulates	  muscarinic	  M2	  receptors	   (Gαi	   GPCRs),	   also	   exhibits	   anti-­‐adrenergic	   effects	   and	   evidence	   suggests	   that	  activation	  of	  PP2A	  downstream	  of	  the	  receptors	  is	  responsible	  for	  this.135,136	  	  








 Role	  of	  association	  with	  Pak1	  1.5.1.4An	  emerging	  concept	  in	  cardiac	  PP2A	  signaling	  is	  the	  holoenzyme’s	  association	  with	  p21-­‐activated	  kinase	  1	  (Pak1).	  Pak1	  is	  a	  Ser/Thr	  kinase	  activated	  by	  Rho	  GTPases	  Cdc42	  and	  Rac1.138	  PP2A	  and	  Pak1	   form	  signaling	   complexes	   in	   the	  brain139	   and	  studies	   in	   isolated	  myocytes	   suggested	   that	   these	   complexes	   exist	   in	   the	   heart.140	   In	   isolated	   myocytes,	  adenoviral	  expression	  of	  constitutively	  active	  Pak1	  caused	  a	  reduced	  myofilament	  protein	  phosphorylation.140	   Furthermore,	   it	   was	   associated	   with	   reduced	   PP2A	   C	   subunit	   Y307	  phosphorylation,	  suggesting	  that	  PP2A	  activity	  was	  increased	  in	  these	  cells.140	  Sheehan	  et	  
al.	   proposed	   a	   signaling	   scheme	   in	   which	   cardiac	   PP2A	   is	   associated	   with	   Pak1	   and	   is	  activated	  by	  Cdc42/Rac1	  downstream	  of	  Gαi	  GPCRs.141	   It	  was	  proposed	  that	  this	  mode	  of	  PP2A	   activation	   might	   regulate	   the	   phosphorylation	   of	   PKA	   substrates	   in	   response	   to	  sympathetic	  stimulation.141	  	  
1.5.2 PP2A	  in	  cardiac	  pathophysiology	  
 Role	  in	  cardiac	  hypertrophy	  and	  failure	  1.5.2.1Heart	   failure	   (HF)	   is	   a	   progressive	   disease.	   It	   is	   the	   end	   point	   of	   a	   wide	   range	   of	  cardiovascular	  disorders	  and	  is	  a	  leading	  cause	  of	  morbidity	  and	  mortality.142	  The	  cause	  of	  HF	  may	  be	  abrupt	   (e.g.	  myocardial	   infarction),	   gradual	   (e.g.	   hypertension)	  or	  hereditary	  (e.g.	  familial	  hypertrophic	  cardiomyopathy);	  in	  all	  cases	  the	  heart	  deteriorates	  to	  a	  point	  at	  which	   it	  can	  no	   longer	  sustain	   the	  needs	  of	   the	  peripheral	  organs.143	   Insults	   to	   the	  heart	  can	   induce	   pathological	   hypertrophy	   and	   adverse	   remodeling,	   which	   correlate	   with	  increased	   expression	   of	   the	   fetal	   cardiac	   genes	   and	   decreased	   expression	   of	   the	   adult	  cardiac	  genes.144	  In	  the	  early	  stages	  of	  heart	  disease	  the	  body	  initiates	  adaptive	  responses	  (e.g.	  neurohormonal	  activation)	   to	   restore	   the	  cardiac	  output.145	  Nevertheless,	  over	   time	  these	  persistent	  alterations	  cause	  further	  damage	  to	  the	  heart	  and	  hasten	  its	  demise.145	  	  








increased	  activity	  of	  protein	  phosphatases.146	  This	  was	  suggested	  on	  the	  basis	  of	  studies	  in	  a	   rat	  model	  of	  hypertrophy	   induced	  by	   long-­‐term	  stimulation	  of	  β-­‐ARs.146	   In	   this	  model,	  left	  ventricular	  (LV)	  dysfunction	  was	  associated	  with	  reduced	  phosphorylation	  of	  PLB	  at	  S16	  and	  T17,	  and	  increased	  activity	  of	  PP1	  and	  PP2A.146	  	  
Increased	  activity	  of	  cardiac	  PP2A	  was	  also	  reported	  in	  a	  mouse	  model	  of	  alveolar	  hypoxia	  with	   associated	   cardiac	   diastolic	   dysfunction.147	   In	   mice,	   the	   diastolic	   dysfunction	   was	  attributed	  to	  the	  reduced	  phosphorylation	  of	  PLB	  at	  S16,	  through	  the	  increased	  expression	  of	  PP2A	   induced	  by	   increased	   levels	  of	   circulating	   interleukin-­‐18.147	  This	  was	  supported	  by	   observations	   (in	   isolated	   cardiac	   cells)	   that	   this	   inflammatory	   cytokine	   induced	   an	  increase	   in	   the	   expression	   of	   PP2A	   and	   a	   parallel	   decrease	   in	   the	   phosphorylation	   of	  PLB.147	  	  








Decreased	   cardiac	   PP2A	   expression	   and	   activity	   was	   reported	   in	   a	   mouse	   model	   of	  sepsis.152	   Sepsis	   is	   a	   systemic	   inflammatory	   response	   to	   an	   infection153	   and	   cardiac	  depression	   is	   a	   frequent	   complication	   in	   this	   condition.154	   In	   this	   context,	   the	   isolated	  cardiac	   myocytes	   of	   septic	   rats	   and	   mice	   exhibit	   an	   impaired	   contractility	   through	   the	  sustained	   phosphorylation	   of	   cTnI	   (S23/24)	   and	   increased	   myofilament	   calcium	  sensitivity.152,155	   As	   suggested	   by	   studies	   in	  mice,	   increased	   cTnI	   phosphorylation	   is	   the	  consequence	   of	   the	   reduced	   expression	   and	   activity	   selected	   PP2A	   holoenzymes	   (i.e.	  B56α-­‐PP2A).152	  	  
As	  described	  in	  an	  earlier	  section	  of	  this	  general	  introduction,	  class	  II	  HDACs	  prevent	  the	  onset	   of	   hypertrophy	   by	   repressing	  MEF2	   in	   the	   nucleus.52	  Hypertrophic	   stimuli	   induce	  nuclear	   export	   of	   class	   II	   HDAC,	   resulting	   in	   increased	   transcription	   of	   MEF2	   genes.52	  Studies	  in	  transgenic	  mice	  with	  increased	  cardiac	  expression	  of	  casein	  kinase-­‐2	  interacting	  protein-­‐1	  (CKIP-­‐1)	  suggest	   that	  PP2A	  represses	  hypertrophy	  and	  the	  proposed	  signaling	  pathway	  involves	  dephosphorylation	  of	  HDAC4	  at	  S246	  by	  CKIP-­‐1-­‐recruited	  PP2A.156	  	  








Transgenic	  mice	  with	  muscle-­‐specific	  expression	  of	  a	  mutant	  PP2A	  scaffold	  subunit	  (AΔ5)	  have	  also	  been	  studied.159	  The	  mice	  expressed	  a	  dominant	  negative	  mutant	  of	  the	  human	  protein	  lacking	  HEAT5,	  hence	  AΔ5.159	  This	  mutated	  subunit,	  which	  binds	  the	  C	  subunit	  but	  not	  the	  B-­‐type	  subunit,	  caused	  a	  form	  of	  dilated	  cardiomyopathy.159	  The	  expression	  of	  AΔ5	  was	   associated	  with	   an	   increase	   in	   the	   core	   enzyme-­‐to-­‐holoenzyme	   ratio	   and,	   albeit	   by	  unknown	   mechanisms,	   induced	   an	   increase	   in	   heart	   weight-­‐to-­‐body	   weight	   ratio	   at	  birth.159	   The	   chambers	   of	   the	   heart	   were	   enlarged,	   their	   walls	   were	   thinner	   and	   the	  systolic	  function	  was	  impaired.159	   	  
 Role	  in	  ischaemia/reperfusion-­‐induced	  injury	  1.5.2.2Liu	  and	  Hofmann	   reported	  a	   role	   for	  PP2A	   in	  oxidative	   stress-­‐induced	  apoptosis.160	  p38	  mitogen-­‐activated	  protein	  kinase	  (MAPK)	  and	  ERK	  signal	  in	  opposing	  pathways	  and	  whilst	  p38	  MAPK	  is	  pro-­‐apoptotic,	  ERK	  is	  anti-­‐apoptotic.161	  Studies	  in	  isolated	  cardiac	  cells	  show	  that	  reactive	  oxygen	  species	  activate	  p38	  MAPK	  and	  ERK	  simultaneously,	  and	  suggest	  that	  during	   oxidative	   stress	   p38	   MAPK	   attenuates	   ERK	   phosphorylation	   (and	   activation)	   by	  stimulating	  PP2A	  activity.160	  The	  underlying	  mechanism	  for	  this	  response	  was	  not	  defined.	  	  
Snabaitis	  et	  al.	   showed	   that	   PP2A	   regulates	  NHE1	   activity	   downstream	  of	   adenosine	  A1	  receptors.162	   NHE1	   is	   a	   sodium	   and	   hydrogen	   exchanger	   that	   regulates	   intracellular	   pH	  and	   its	   activity	   is	   increased	   by	   phosphorylation.163	   In	   isolated	  myocytes,	   phenylephrine	  induces	  p90	  ribosomal	  S6	  kinase-­‐mediated	  phosphorylation	  of	  NHE1	  and	  this	  is	  inhibited	  by	  co-­‐stimulation	  with	  CPA.162	  Snabaitis	  et	  al.	  showed	  that	  CPA	  caused	  the	  accumulation	  of	  PP2A	  at	  the	  cell	  membrane	  and	  that	  PP2A	  activity	  was	  necessary	  for	  the	  inhibitory	  effect	  of	  CPA	  on	  phenylephrine-­‐induced	  NHE1	  phosphorylation	  and	  activation.162	  Therefore,	   in	  the	   context	   of	   adenosine	   A1	   receptor	   stimulation	   during	   ischemia	   and	   reperfusion,	   this	  study	  suggests	  a	  cardio-­‐protective	  role	  for	  PP2A.	  	  








subunits	  is	  limited	  by	  the	  scarcity	  of	  appropriate	  mouse	  models	  and	  the	  first	  report	  on	  the	  consequences	  of	  knocking	  out	  an	  individual	  B-­‐type	  subunit	  (B56δ)	  in	  mice	  appeared	  only	  in	  2011.120	  Thus,	  much	  of	  the	  relevant	  information	  to	  date	  has	  been	  obtained	  from	  studies	  in	  isolated	  cardiac	  myocytes	  or	  inferred	  from	  studies	  in	  immortalized	  cell	  lines.	  	  
 B56	  subunits	  1.5.3.1
 B56α	  1.5.3.1.1Ankyrin	   proteins	   organize,	   transport	   and	   anchor	   membrane	   proteins	   to	   the	  cytoskeleton164	  and	  ankyrin-­‐B	  has	  been	   implicated	   in	   the	   targeting	  of	  B56α.119	   In	  mouse	  ventricular	  myocytes,	  B56α	  is	  localized	  at	  the	  M-­‐line	  and	  a	  smaller	  population	  is	  localized	  at	  the	  Z-­‐disk.119	  This	  distribution	  is	  governed	  by	  the	  interaction	  with	  ankyrin-­‐B	  and	  results	  from	   an	   ankyrin-­‐binding	   motif	   at	   the	   C-­‐terminus	   of	   the	   regulatory	   subunit.119	   The	  sequence	  of	  14	  amino	  acids	  is	  conserved	  in	  human,	  mouse	  and	  rat	  isoforms	  and	  does	  not	  exist	   in	   other	   B56	   family	   members,	   suggesting	   that	   only	   B56α	   binds	   ankyrin-­‐B.119	   The	  critical	   role	   of	   this	   adaptor	   protein	   in	   the	   targeting	   of	   B56α	   is	   highlighted	   by	   the	   near-­‐complete	   loss	   of	   its	   M-­‐line	   localization	   in	   cardiac	   myocytes	   of	   ankyrin-­‐B-­‐null	   mice.119	  Nevertheless,	  a	  minor	  population	  of	  B56α	  localizes	  in	  a	  manner	  that	  is	  not	  dependent	  on	  the	   presence	   of	   ankyrin-­‐B.119	   In	   related	   studies	   it	   was	   determined	   that	   ankyrin-­‐B	   and	  PP2A	   are	   localized	   at	   the	  M-­‐line	   by	   obscurin.165	   The	   targets	   of	   ankyrin-­‐B-­‐targeted	  PP2A	  were	  not	  reported	  in	  either	  study.	  	  
Studies	   in	   our	   laboratory	   showed	   that	   in	   isolated	   ARVM,	   ISO	   altered	   the	   subcellular	  distribution	  of	  B56α.166	  This	  was	   initially	   revealed	  by	  proteomics	  analysis	  of	   the	   cardiac	  myofilament	  subproteome	  and	  was	  confirmed	  by	  immunofluorescence	  studies	  of	  B56α	  in	  isolated	  “skinned”	  cardiac	  cells.166	  B56α	  localized	  at	  the	  Z-­‐disc	  and	  M-­‐line	  in	  unstimulated	  cells	  and	  was	  lost	   from	  both	  regions	  following	  β-­‐AR	  stimulation.166	  Overall,	   these	  studies	  suggested	   the	   intriguing	   possibility	   that	   dynamic	   changes	   in	   PP2A	   targeting	   regulate	  protein	  phosphorylation	  in	  response	  β-­‐AR	  stimulation.	  	  








mRNA.167	  MiR-­‐1,	  a	  muscle-­‐specific	  microRNA,	   is	  up-­‐regulated	   in	  HF168	  and	  the	   functional	  role	   of	   this	  micro-­‐RNA	  was	   explored	   in	   isolated	   ARVM	  with	   heterologous	   expression	   of	  miR-­‐1.169	  In	  these	  cells,	  the	  amplitude	  of	  the	  inward	  calcium	  current	  and	  the	  frequency	  of	  spontaneous	  SR	  calcium	  release	  were	  increased.169	  Respectively,	  these	  effects	  were	  caused	  by	  increased	  phosphorylation	  of	  LTCCs	  (site	  not	  reported)	  and	  increased	  phosphorylation	  of	   RyR2s	   (S2814).169	   These	   alterations	   resulted	   from	   the	   reduced	   expression	   of	   B56α	  through	  translational	  inhibition	  of	  the	  mRNA	  transcript.169	  At	  the	  molecular	  level	  this	  was	  explained	  by	   the	  presence	  of	  a	  seed	  sequence	   in	   the	  3’-­‐untranslated	  region	  (UTR)	  of	   the	  B56α	   mRNA	   transcript,	   which	   is	   complementary	   to	   miR-­‐1.169	   Therefore,	   miR-­‐1	   altered	  calcium	   signaling	   in	   the	   isolated	   cells	   by	   down-­‐regulating	   a	   population	   of	   PP2A	  holoenzymes,	  i.e.	  B56α-­‐PP2A.	  	  
The	   stress-­‐induced	   cardiac	   hypertrophy	   and	   remodeling	   in	   HF	   is	   partly	   mediated	   by	  MAPK	   signaling.170	   Stress-­‐induced	   changes	   in	   PP2A	   gene	   expression	   were	   studied	   in	  isolated	   cardiac	   cells	   with	   sustained	   activation	   of	   stress-­‐activated	   c-­‐Jun	   N-­‐terminal	  kinase.171	  In	  these	  cells,	  the	  abundance	  of	  B56α	  protein	  was	  reduced	  through	  a	  reduction	  in	  the	  stability	  of	  the	  mRNA	  transcript	  and	  this	  was	  attributed	  to	  the	  presence	  of	  AU-­‐rich	  elements	  (AREs)	  in	  the	  3’-­‐UTR.171	  AREs	  are	  targeted	  by	  ARE/poly(U)-­‐binding/degradation	  factor	  1	  (which	  is	  up-­‐regulated	  in	  this	  cell	  model	  of	  cardiac	  stress)	  and	  thereby	  contribute	  to	  mRNA	   instability.171	   Although	   there	   is	   no	   evidence	   that	   this	   is	   the	   case,	   such	   stress-­‐induced	  reduction	  in	  B56α	  mRNA	  stability	  might	  explain	  the	  loss	  of	  cardiac	  B56α	  protein	  in	  septic	  mice,	  described	  in	  section	  1.5.2.1.	  	  








 B56γ	  1.5.3.1.2Gigena	   et	   al.	   studied	   the	   subcellular	   distribution	   of	   B56γ1	   in	   isolated	   rat	   ventricular	  myocytes	   with	   heterologous	   expression	   of	   hemagglutinin	   (HA)-­‐tagged	   B56γ1.	   Confocal	  images	  of	  the	  cells	  showed	  that	  HA-­‐B56γ1	  was	  primarily	  localized	  in	  the	  nucleus	  and	  that	  it	   was	   concentrated	   in	   nuclear	   speckles,	   which	   are	   rich	   in	   transcription	   factors	   and	  splicing	  factors.111	  In	  contrast,	  HA-­‐B56α	  was	  found	  in	  non-­‐nuclear	  regions	  and	  localized	  in	  the	   myofilaments.111	   In	   related	   studies,	   Zhou	   et	   al.	   used	   an	   affinity-­‐based	   proteomic	  strategy	  to	  identify	  the	  cardiac	  binding	  partners	  of	  B56γ1.173	  This	  method	  relied	  on	  using	  glutathione	   S-­‐transferase	   (GST)-­‐tagged	   B56γ1	   to	   extract	   B56γ1-­‐PP2A	   binding	   partners	  from	   homogenates	   of	   mouse	   heart	   tissue.173	   	   ~30	   putative	   binding	   partners,	   including	  SERCA2a,	  were	  identified	  in	  the	  analysis	  and	  the	  results	  were	  supplemented	  by	  functional	  studies	   in	  ARVM	  expressing	  HA-­‐B56γ1.173	  Over-­‐expression	  of	  B56γ1	  was	   associated	  with	  reduced	   phosphorylation	   of	   the	   pre-­‐mRNA	   splicing	   factor	   ASF/SF2	   and	   reduced	  phosphorylation	  of	  PLB	  at	  S16.173	  ASF/SF2	  has	  been	  implicated	  in	  mRNA	  splicing	  activity	  in	  hypertrophic	  cardiac	  growth	  and	  HF174,175	  but	  the	  potential	  involvement	  of	  B56γ1	  in	  this	  setting	  was	  not	  described.	  The	  functional	  studies	  were	  focused	  on	  ECC;	  over-­‐expression	  of	  B56γ1	  caused	  a	   reduction	   in	   the	  peak	   twitch	  contraction	  under	  basal	   conditions,	  but	  did	  not	  affect	  ISO-­‐induced	  contractility.173	  	  
Recent	   studies	   in	   B56γ-­‐null	  mice	   indicate	   that	   B56γ-­‐PP2A	   activity	   is	   necessary	   in	   heart	  development	   such	   that	   the	   absence	   of	   B56γ	   causes	   the	   incomplete	   formation	   of	   the	  intraventricular	  septum.176	  








Simultaneously,	  PKA	  phosphorylates	  B56δ	  at	  S573,	  stimulating	  PP2A	  activity.	  PP2A	  then	  attenuates	   PDE4D3	   activation	   and	   cAMP	   degradation	   by	   dephosphorylating	   S54.177	  Although	  mice	  with	  global	  deletion	  of	  B56δ	  exist,120	   the	  cardiac	  phenotype	  of	   these	  mice	  was	  not	  reported	  and	  the	  specific	  cardiac	  roles	  of	  this	  regulatory	  subunit	  are	  unknown.	  








1.6 Project	  objectives	  The	  targeting	  of	  PP2A,	  its	  substrate	  specificity	  and	  its	  catalytic	  activity	  are	  regulated	  by	  B-­‐type	  subunits.66	  While	  studies	  in	  transgenic	  mice	  with	  cardiac-­‐specific	  over-­‐expression	  of	  the	  PP2A	  catalytic	  subunit	  suggest	  that	  dysregulated	  PP2A	  activity	   is	  detrimental	   for	  the	  heart,	   the	   specific	   importance	   of	   B-­‐type	   subunits	   in	   the	   regulation	   of	   cardiac	   PP2A	   is	  highlighted	   by	   the	   phenotye	   of	   transgenic	  mice	  with	  muscle-­‐specific	   expression	   of	   AΔ5,	  which	  is	  defective	  in	  binding	  to	  these	  subunits.159	  Our	  understanding	  of	  the	  cardiac	  roles	  and	   regulation	   of	   individual	   B-­‐type	   subunits	   is	   limited	   and	   an	   improved	   understanding	  may	   facilitate	   the	   targeted	   modulation	   of	   cardiac	   PP2A	   holoenzymes	   for	   therapeutic	  benefit.	  Towards	  this	  objective,	  the	  following	  specific	  aims	  were	  addressed	  in	  this	  project:	  
• Determine	  the	  expression	  of	  PP2A	  regulatory	  B56	  subunits	  in	  ARVM.	  	  
• Determine	  the	  basal	  subcellular	  distribution	  of	  B56	  subunits	  in	  ARVM	  and	  investigate	  potential	  changes	  in	  this	  distribution	  in	  response	  to	  β-­‐AR	  stimulation.	  	  
• Determine	   whether	   B56δ	   is	   phosphorylated	   in	   ARVM	   exposed	   to	   the	   β-­‐AR	   agonist	  ISO.	  	  	  
• Characterize	   the	   signaling	   pathway	   that	   underlies	   ISO-­‐induced	   phosphorylation	   of	  B56δ.	  




























Figure	  1.3	  Structure	  and	  catalytic	  mechanism	  of	  PPPs	  









































































modified	   Tyrode	   solution	   containing	   1	   mM	   CaCl2	   and	   cultured,	   as	   described	   in	   section	  2.1.2.	  	  
2.1.2 Culture	  ARVM	  were	  cultured	   in	  wells	  of	  plastic	  6-­‐well	  cell	   culture	  plates	  or	   in	  28	  mm	  single	  cell	  culture	  wells.	  The	  wells	  were	  coated	  with	  laminin	  prior	  to	  cell	  culture	  using	  Natural	  Mouse	  Laminin	  (Invitrogen).	  This	  was	  diluted	  in	  ddH2O	  to	  15	  μg/mL	  and	  1.5	  mL	  of	  the	  solution	  was	   added	   to	   each	   well.	   Plates	   and	   single	   cell	   culture	   wells	   were	   left	   in	   a	   sterile	  environment	  for	  at	  least	  1	  h.	  Laminin	  was	  removed	  and	  the	  wells	  were	  washed	  with	  pre-­‐warmed	  modified	  M199	  medium	  (Invitrogen).	  Tyrode	  solution	  was	  removed	  from	  the	  50	  mL	  conical	   tube	  and	  myocytes,	  settled	  at	   the	  bottom	  of	   the	  tube,	  were	  washed	  with	  pre-­‐warmed	   modified	   M199	   medium.	   Following	   centrifugation	   (300	   rpm,	   2	   min)	   the	   cells	  were	  resuspended	  in	  the	  appropriate	  volume	  of	  modified	  M199	  medium	  (48	  mL	  for	  ARVM	  isolated	  from	  one	  rat	  heart).	  2	  mL	  of	  the	  resulting	  suspension	  was	  added	  to	  each	  culture	  well.	  The	  cells	  were	  incubated	  for	  2	  h	  at	  37oC	  (5%	  CO2)	  after	  which,	  the	  culture	  medium	  was	   replaced	  with	   2	  mL	   of	   fresh	  modified	  M199	  medium.	   Unless	   otherwise	   stated,	   the	  cells	  were	  incubated	  for	  18	  h	  (overnight)	  before	  the	  experiments	  were	  performed.	  	  
2.1.3 Infection	  with	  adenoviruses	  Adenoviral	   infection	   of	   ARVM	   was	   performed	   2	   h	   post-­‐seeding,	   before	   overnight	  incubation.	  The	  culture	  medium	  was	  replaced	  with	  1	  mL	  of	  fresh	  culture	  medium	  and	  cells	  were	  counted	  using	  an	  eyepiece	  graticulate	  that	  covered	  an	  area	  of	  1	  mm2.	  The	  cells	  were	  counted	   in	   three	   distinct	   regions	   of	   the	   well,	   to	   obtain	   an	   average	   cell	   count	   per	   mm2.	  From	  this,	  the	  total	  number	  of	  cells	  per	  well	  and	  the	  volume	  of	  virus	  required	  for	  that	  well	  were	  calculated	  as	  follows:	  
Cells	  per	  well	  =	  cells	  per	  mm2	  x	  962	  mm2	  (i.e.	  surface	  area	  of	  the	  well)	  








2.1.4 Pharmacological	  treatment	  Details	  of	  the	  compounds	  used	  in	  the	  experiments	  described	  in	  this	  thesis	  are	  provided	  in	  Table	  2.1.	  Details	   of	   the	   treatment	  protocols	   are	  provided	   in	   the	  methods	   section	  of	   the	  relevant	  experimental	  chapters.	  
Table	  2.1	  Compounds	  used	  in	  pharmacological	  experiments	  
2.1.5 Subcellular	  fractionation	  	  ARVM	  were	   lysed	   in	   cold	   cell	   lysis	   buffer	   (200	   μL	   per	  well).	   The	   plates	  were	   frozen	   on	  liquid	   nitrogen	   and	   thawed	   at	  RT.	   The	   cells	  were	   detached	   from	   the	   bottom	  of	   the	  well	  using	   a	   cell	   scraper,	   whilst	   resting	   the	   plate	   on	   ice.	   Lysates	   were	   transferred	   to	   a	  microcentrifuge	  tube	  and	  maintained	  on	   ice	   for	  5	  min,	  with	   frequent	  vortexing.	  For	  each	  condition,	   lysates	  were	  pooled	   from	  four	  wells.	  For	   immunoblot	  analysis	  of	   total	  protein	  expression,	  100	  μL	  of	  lysate	  was	  transferred	  to	  a	  microcentrifuge	  tube	  and	  to	  this,	  50	  μL	  of	  3X	  Laemmli	   sample	  buffer	  was	   added.	  The	   remaining	  700	  μL	  of	   lysate	  was	   subjected	   to	  centrifugation	  (14000	  g,	  30	  min,	  4oC).	  The	  supernatant,	   containing	  soluble	  proteins,	  was	  transferred	  to	  a	  microcentrifuge	  tube	  and	  to	  this,	  350	  μL	  of	  3X	  Laemmli	  sample	  buffer	  was	  added.	  The	  pellet,	  containing	  insoluble	  proteins,	  was	  resuspended	  in	  1X	  Laemmli	  sample	  buffer	  (1050	  μL	  to	  study	  relative	  subunit	  distribution	  or	  300	  μL	  to	  study	  translocation).	  A	  schematic	  overview	  of	  the	  fractionation	  method	  is	  shown	  in	  Figure	  2.1.	   	  
















2.3 Protein	  Biochemistry	  2.3.1 Determination	  of	  protein	  concentration	  	  Protein	   concentration	  was	   determined	   in	   the	  Bradford	   assay,	   using	   the	  Bio-­‐Rad	  Protein	  Assay	  Dye	  Reagent	  Concentrate	  (Bio-­‐Rad,	  500-­‐0006).	  The	  dye	  was	  prepared	  by	  diluting	  1	  part	  of	  Dye	  Reagent	  Concentrate	  with	  4	  parts	  of	  ddH2O.	  BSA	  standards	  containing	  between	  0.1	   and	   0.5	  mg/mL	   BSA	  were	   prepared	   in	  wells	   of	   a	   96-­‐well	  microtitre	   plate	   using	   a	   1	  mg/mL	  BSA	  working	   solution,	   as	   indicated	   in	   Table	   2.2.	   200	   μL	   of	   the	   dye	   reagent	  was	  added	   to	   each	   standard	   and	   the	   colour	   was	   allowed	   to	   develop	   for	   5	   min	   at	   RT.	  Absorbance	  was	  measured	  at	  595	  nm	  in	  a	  BioTek	  ELx808	  Plate	  Reader.	  A	  standard	  curve	  was	  plotted	  and	  used	  to	  determine	  the	  protein	  concentration	  of	  the	  samples.	  
Table	  2.2	  Preparation	  of	  BSA	  standards	  
2.3.2 Electrophoretic	  protein	  separation	  Proteins	   were	   separated	   by	   sodium	   dodecyl	   sulfate	   polyacrylamide	   gel	   electrophoresis	  (SDS-­‐PAGE).	  The	  gels	  were	  hand-­‐cast	  using	  1.5	  mm	  thick	  spacer	  plates	  and	  consisted	  of	  a	  lower	  resolving	  gel	  and	  an	  upper	  stacking	  gel.	  The	  acrylamide	  content	  of	  the	  resolving	  gel	  was	  determined	  by	  the	  molecular	  weight	  of	  the	  protein	  of	  interest.	  The	  composition	  of	  the	  gels	  is	  indicated	  in	  Table	  2.3.	  Cell	  or	  tissue	  samples	  were	  heat-­‐denatured	  at	  95oC	  for	  5	  min	  immediately	   before	   use.	   Electrophoresis	   was	   performed	   in	   1X	   reservoir	   buffer	   at	   a	  constant	  voltage	  of	  150	  V.	  	   	  








Table	  2.3	  Composition	  of	  resolving	  and	  stacking	  gels	  used	  for	  SDS-­‐PAGE	  
2.3.3 Electrophoretic	  protein	  transfer	  	  For	  semi-­‐dry	  protein	  transfer,	  the	  gels	  were	  equilibrated	  in	  semi-­‐dry	  transfer	  buffer	  for	  10	  min	  before	   electrophoretic	   protein	   transfer	   to	   a	   polyvinylidene	   fluoride	   (PVDF)	  blotting	  membrane.	   Blotting	   papers	   and	   membranes	   were	   pre-­‐soaked	   in	   transfer	   buffer	   and	   a	  transfer	  sandwich	  was	  assembled	  in	  a	  semi-­‐dry	  transfer	  unit.	  Protein	  transfer	  proceeded	  at	  a	  constant	  current	  of	  45	  mA	  per	  gel	  (maximum	  of	  six	  gels	  per	  transfer	  unit)	  for	  2	  h	  at	  room	   temperature	   (RT).	   For	   wet	   protein	   transfer,	   the	   gels	   were	   equilibrated	   in	   wet	  transfer	  buffer	   for	  10	  min	  before	  electrophoretic	   transfer	  of	  proteins	   to	  a	  PVDF	  blotting	  membrane.	   Blotting	   papers	   and	   membranes	   were	   pre-­‐soaked	   in	   transfer	   buffer	   and	   a	  transfer	  sandwich	  was	  assembled	  on	  a	  gel	  holder	  cassette	  of	  a	  Bio-­‐Rad	  Criterion	  Blotter.	  Proteins	   were	   transferred	   towards	   the	   positive	   electrode	   at	   a	   constant	   voltage	   of	   90	   V	  (maximum	  of	  two	  gels	  per	  blotting	  tank)	  for	  90	  min	  at	  4oC.	  	  
2.3.4 Immunoblot	  analysis	  	  Non-­‐specific	  binding	  was	  blocked	  by	   incubating	   the	  membranes	   in	  TBS	   containing	  0.1%	  (v/v)	   Tween-­‐20	   (TBST)	   and	   10%	   (w/v)	   milk	   powder	   for	   2	   h	   at	   RT.	   Subsequently,	   the	  membranes	  were	   incubated	   in	  primary	  antibody	  overnight	  at	  4oC.	  The	  membranes	  were	  washed	   four	   times	   in	   TBST	   (15	  min	   per	   wash)	   and	   were	   incubated	   in	   HRP-­‐conjugated	  secondary	  antibody	   for	  2	  h	  at	  RT.	  The	  membranes	  were	  washed	   four	   times	   in	  TBST	  (15	  
















Table	  2.4	  Primary	  antibodies	  used	  for	  immunoblot	  analysis	  
Table	  2.5	  Secondary	  antibodies	  used	  for	  immunoblot	  analysis	  
2.3.5 Phos-­‐tagTM	  SDS-­‐PAGE	  and	  immunoblot	  analysis	  	  Proteins	  were	  separated	  by	  electrophoresis	  under	  reducing	  and	  denaturing	  conditions	  in	  a	  discontinuous	   polyacrylamide	   gel	   system.	  Gels	  were	   hand-­‐cast	   using	   1	  mm	   thick	   spacer	  plates	  and	  consisted	  in	  a	  lower	  resolving	  gel	  and	  an	  upper	  stacking	  gel.	  50	  μM	  acrylamide-­‐pendant	  Phos-­‐tagTM	  (Wako	  Pure	  Chemical	  Industries)	  and	  100	  μM	  MnCl2	  were	  included	  in	  the	  resolving	  gel.	  The	  composition	  of	   the	  resolving	  and	  stacking	  gel	   is	   indicated	   in	  Table	  2.6.	  Electrophoresis	  was	  performed	  in	  1X	  reservoir	  buffer	  at	  a	  constant	  current	  of	  25	  mA	  per	  gel.	  The	  Gels	  were	  equilibrated	  in	  wet	  transfer	  buffer	  with	  2	  mM	  EDTA	  for	  15	  min	  then	  in	   transfer	   buffer	   without	   EDTA	   for	   10	   min.	   Proteins	   were	   transferred	   to	   a	   PVDF	  
Primary	  antibody	   Supplier	  and	  catalogue	  no.	   Dilution	  α-­‐Actinin	   	   Sigma	  Aldrich,	  A7732	   1:5000	  	  α1NKA	   	   Calbiochem,	  05-­‐369	   1:1000	  	  B56α	   BD	  Biosciences,	  610615	   1:1000	  	  B56γ	   Abcam,	  Ab94633	   1:500	  	  B56δ	   Bethyl	  Laboratories,	  A301-­‐100A	   1:1000	  	  pS573	  B56δ	  	   Gift	  from	  Angus	  Nairn	   1:2000	  	  cMyBP-­‐C	   Gift	  from	  Mathias	  Gautel	   1:30	  000	  	  pS282	  cMyBP-­‐C	  	   Enzo	  Life	  Sciences,	  ALX-­‐215-­‐057-­‐R050	   1:2000	  	  cTnI	   Cell	  Signaling	  Technology,	  4002	   1:1000	  	  pS23/24	  cTnI	  	   Cell	  Signaling	  Technology,	  4004	   1:1000	  	  GAPDH	   Abcam,	  Ab9482	   1:5000	  	  GFP	   Roche,	  11814460001	   1:500	  	  Histone	  2B	   Abcam,	  ab1790-­‐100	   1:1000	  Phospho-­‐PKA	  substrate	   Cell	  Signaling	  Technology,	  9624	   1:3000	  	  PLB	   Cell	  Signaling	  Technology,	  8595	   1:1000	  	  pS16	  PLB	  	   Badrilla,	  A010-­‐12AP	   1:1000	  PP2A	  catalytic	   Cell	  Signaling	  Technology,	  2038	   1:1000	  	  PP2A	  scaffold	   	   Santa	  Cruz	  Biotechnology,	  sc-­‐74580	   1:1000	  	  








membrane	  by	  wet	  transfer,	  as	  described	  in	  section	  2.3.3.	  Immunoblot	  analysis	  and	  protein	  detection	  were	  carried	  out	  as	  described	  in	  section	  2.3.4.	  
Table	  2.6	  Composition	  of	  resolving	  and	  stacking	  gels	  used	  for	  Phos-­‐tagTM	  SDS-­‐PAGE	  
	   	  
















Table	  2.7	  Primary	  antibodies	  used	  for	  confocal	  microscopy	  
Table	  2.8	  Secondary	  antibodies	  and	  fluorescent	  dyes	  used	  for	  confocal	  microscopy	  
2.5 Construction	  of	  adenoviral	  vectors	  2.5.1 Plasmids	  pEGFP-­‐C1	   (Figure	   2.2)	  was	   a	   kind	   gift	   from	  Veerle	   Janssens	   (KU	   Leuven,	   Belgium).	   The	  plasmid,	   carrying	   the	   cDNA	   of	   human	   B56δ	   (UniProt	   entry	   Q14738),	   was	   used	   as	   the	  template	   plasmid	   from	   which	   the	   green	   fluorescent	   protein	   (GFP)-­‐fusion	   gene	   was	  derived.	  pShuttle-­‐CMV	  (Stratagene,	  Figure	  2.3)	  was	  used	  as	  the	  shuttle	  vector	  into	  which	  the	   gene	   of	   interest	   (GOI)	   was	   subcloned.	   The	   kanamycin	   cassette	   present	   within	   this	  plasmid	  provides	  bacterial	  resistance	  to	  the	  antibiotic	  kanamycin.	  pAdEasy-­‐1	  (Stratagene,	  Figure	   2.3)	   was	   used	   to	   generate	   recombinant	   adenoviral	   DNA.	   The	   plasmid,	   which	  contains	  most	   of	   the	   human	   adenovirus	   serotype	   5	   (AdV)	   genome,	   lacks	   the	   E1	   and	   E3	  genes	  and	  as	  such,	  is	  replication-­‐deficient.	  	  
2.5.2 DNA	  gel	  electrophoresis	  	  DNA	   was	   resolved	   by	   electrophoresis	   in	   0.8%	   or	   1%	   agarose	   TAE	   gels	   containing	   the	  nucleic	   acid	   stain	   GelRed	   (Cambridge	   Biosciences).	   The	   composition	   of	   the	   gels	   is	  indicated	   in	   Table	   2.1.	   The	   Gels	   were	   run	   at	   100	   volts	   and	   the	   DNA	  was	   visualized	   by	  exposure	   to	   UV	   light	   in	   a	   G:BOX	   Chemi	   XT16	   Gel	   Documentation	   and	   Analysis	   System	  (Syngene).	  	  
Primary	  antibody	   Supplier	  and	  catalogue	  no.	   Working	  dilution	  α-­‐Actinin	   	   Sigma	  Aldrich,	  A7732	   1:100	  B56δ	   Bethyl	  Laboratories,	  A301-­‐100A	   1:200	  








Table	  2.9	  Composition	  of	  agarose	  TAE	  gels	  used	  for	  DNA	  electrophoresis	  
2.5.3 Site-­‐directed	  mutagenesis	  	  A	   single	   point	   mutation	   was	   introduced	   into	   the	   cDNA	   of	   human	   B56δ	   using	   the	  QuikChange	   II	   Site-­‐Directed	   Mutagenesis	   Kit	   (Agilent),	   to	   replace	   the	   Ser	   residue	   at	  position	  573	  with	  alanine	  (Ala,	  A).	  The	  sequences	  of	  the	  forward	  (Fwd)	  and	  reverse	  (Rev)	  mutagenic	  primers	  are	  shown	  in	  Table	  2.10.	  Mutated	  bases	  are	  underlined.	  pEGFP-­‐C1	  was	  used	  as	  template	  DNA.	  A	  site-­‐directed	  mutagenesis	  reaction	  comprised:	  5	  μL	  10X	  Reaction	  Buffer;	  10	  ng	  template	  DNA;	  125	  ng	  S573A	  Fwd	  primer;	  125	  ng	  S573A	  Rev	  primer;	  1	  μL	  dNTP	  mix;	  3	  μL	  QuikSolution	  and	  2.5	  U	  PfuUltra	  HF	  DNA	  Polymerase,	  in	  a	  final	  volume	  of	  50	   μL.	   Reactions	   were	   cycled	   as	   indicated	   in	   Table	   2.11.	   Following	   site-­‐directed	  mutagenesis,	   the	   DNA	   was	   treated	   with	   10	   U	   of	   DpnI	   for	   1	   hour	   at	   37oC,	   to	   digest	  methylated	  and	  hemimethylated	  template	  DNA.	  Plasmid	  DNA	  was	  sent	   to	  Eurofins	  MWG	  Operon	   (Ebersberg,	   Germany)	   for	   sequencing,	   to	   confirm	   successful	   site-­‐directed	  mutagenesis.	  




Agarose	  TAE	  gel	   Composition	  0.8%	  	   2	  mL	  50X	  TAE,	  198	  mL	  	  ddH2O	  ,	  0.8	  g	  agarose,	  10	  μL	  GelRed	  1%	   2	  mL	  50X	  TAE,	  198	  mL	  	  ddH2O	  ,	  0.8	  g	  agarose,	  10	  μL	  GelRed	  








Table	  2.11	  Site-­‐directed	  mutagenesis	  cycling	  parameters	  	  
2.5.4 Polymerase	  chain	  reaction	  The	  cDNA	  encoding	  GFP-­‐B56δ-­‐WT	  and	  GFP-­‐B56δ-­‐S573A	  was	  amplified	  from	  the	  original	  pEGFP-­‐C1	  plasmid	  and	  the	  mutated	  pEGFP-­‐C1	  plasmid,	  respectively,	  by	  polymerase	  chain	  reaction	   (PCR).	   To	   enable	   subcloning	   of	   the	   GOI	   into	   pShuttle-­‐CMV,	   PCR	   primers	   were	  designed	  such	  that	  restriction	  sites	  for	  KpnI	  and	  NotI	  were	  introduced	  at	  the	  5’	  and	  3’	  end	  of	   the	   GOI,	   respectively.	   The	   sequences	   of	   the	   Fwd	   and	   Rev	   PCR	   primers	   are	   shown	   in	  Table	   2.12.	   Restriction	   sites	   are	   underlined.	   A	   PCR	   reaction	   comprised:	   1X	   Phusion	   HF	  buffer;	   200	   μM	   dNTP	   mix;	   0.2	   μM	   KpnI	   Fwd	   primer;	   0.2	   μM	   NotI	   Rev	   primer;	   10	   ng	  template	  plasmid	  and	  1	  U	  Phusion	  DNA	  polymerase,	  in	  a	  final	  volume	  of	  50	  μL.	  Reactions	  were	  cycled	  as	  indicated	  in	  Table	  2.13.	  PCR	  reaction	  products	  were	  purified	  as	  described	  in	  section	  2.5.5.	  	  
Table	  2.12	  PCR	  primers	  	  
	  
Table	  2.13	  PCR	  cycling	  parameters	  
Segment	   Number	  of	  cycles	   Temperature	   Time	  1	   1	   95oC	  -­‐	  denaturation	   1	  min	  2	   18	   94oC	  -­‐	  denaturation	  60oC	  -­‐	  primer	  annealing	  68oC	  -­‐	  extension	   50	  s	  50	  s	  7	  min	  30	  s	  3	   1	   68oC	  	  -­‐	  final	  extension	   7	  min	  30	  s	  
Primer	   Sequence	  
KpnI	  Fwd	   5’atggtacccaccatggtgagcaagggcgag3’ 
NotI	  Rev	   5’gactgcggccgctcagagagcctcctggct3’ 








2.5.5 Purification	  of	  PCR	  products	  DNA	   was	   purified	   using	   the	   High	   Pure	   PCR	   Product	   Purification	   Kit	   (Roche).	   All	  centrifugation	   steps	  were	  performed	   at	   13000	   rpm	   in	   a	   bench-­‐top	  microcentrifuge.	   The	  volume	  of	  the	  reaction	  was	  adjusted	  to	  100	  μL	  with	  ddH2O.	  500	  μL	  of	  Binding	  Buffer	  was	  added	   and	   the	   resulting	   solution	   was	   transferred	   to	   a	   High	   Pure	   Filter	   Tube.	   This	   was	  centrifuged	   for	   1	  min.	   The	   flowthrough	  was	   discarded	   and	   500	   μL	   of	  Wash	   Buffer	  was	  added	   to	   the	   upper	   reservoir	   of	   the	   filter	   tube.	   This	  was	   centrifuged	   for	   1	  min	   and	   the	  process	  was	  repeated.	  DNA	  was	  eluted	  from	  the	  filter	  by	  centrifugation,	  following	  addition	  of	  50	  μL	  Elution	  Buffer.	  	  	  	  	  	  	  
2.5.6 DNA	  restriction	  digest	  	  The	  GOI	  and	  pShuttle-­‐CMV	  were	  digested	  (in	  separate	  reactions)	  with	  10	  U	  of	  both	  KpnI	  and	  NotI	  in	  1X	  NEBuffer	  4	  and	  BSA	  (100	  μg/mL),	  in	  a	  total	  volume	  of	  60	  μL	  for	  1	  hour	  at	  37oC.	   The	   GOI	   and	   shuttle	   vector	   were	   purified	   as	   described	   in	   section	   2.1.5.	   The	   DNA	  concentration	   was	   determined	   using	   a	   NanoDrop	   2000	   UV-­‐Vis	   Spectrophotometer	  (Thermo	  Scientific).	  	  	  
2.5.7 DNA	  ligation	  	  The	   amount	   of	   insert	   (GOI)	   required	   for	   ligation	   with	   50	   ng	   of	   pShuttle-­‐CMV	   shuttle	  vector,	  for	  a	  3:1	  insert-­‐to-­‐vector	  mole	  ratio,	  was	  calculated	  using	  the	  following	  equation.	  	  
Insert	  (ng)	  =	  [vector	  (ng)	  x	  size	  of	  insert	  (kb)	  x	  3]	  ÷	  Size	  of	  vector	  (kb)	  








2.5.8 Transformation	  of	  E.coli	  DH5α	  competent	  cells	  	  Subcloning	  efficiency	  DH5α	  competent	  cells	  (Invitrogen)	  were	  stored	  at	  -­‐80oC	  and	  thawed	  on	  ice	  prior	  to	  the	  transformation.	  5	  μL	  of	  plasmid	  DNA	  was	  added	  to	  50	  μL	  of	  cells.	  These	  were	  maintained	  on	  ice	  for	  30	  min	  and	  were	  heat-­‐shocked	  at	  42oC	  for	  30	  s.	  The	  cells	  were	  incubated	   on	   ice	   for	   2	   min	   and	   resuspended	   in	   500	   μL	   of	   pre-­‐warmed	   SOC	   medium.	  Finally,	   the	   cells	  were	   incubated	   in	   a	  bench-­‐top	   shaker	   (37oC,	   500	   rpm)	   for	  1	  hour.	  The	  cultures	  were	  spread	  on	  LB-­‐kanamycin	  agar	  plates	  and	  the	  inverted	  plates	  were	  incubated	  overnight	  at	  37oC.	  	  	  
2.5.9 Transformation	  of	  E.coli	  BJ5183	  electrocompetent	  cells	  	  Clones	   of	   pShuttle-­‐CMV	   that	   contained	   the	   GOI	   were	   digested	  with	   10	   U	   of	   PmeI	   in	   1X	  NEBuffer	   4	   and	   BSA	   (100	   μg/mL),	   in	   a	   total	   volume	   of	   30	   μL	   for	   1	   hour	   at	   37oC.	   To	  generate	   recombinant	   adenoviral	   DNA	   (rAd5-­‐GOI)	   homologous	   recombination	   between	  pShuttle-­‐CMV-­‐GOI	   pAdEasy-­‐1	   was	   performed	   in	   E.coli	   BJ5183-­‐AD-­‐1	   electrocompetent	  cells	   (Stratagene).	   The	   cells	   were	   stored	   at	   -­‐80oC	   and	   thawed	   on	   ice	   prior	   to	   the	  transformation.	  40	  μL	  of	  cells	  were	  added	  to	  100ng	  (1	  μL)	  of	  PmeI-­‐digested	  pShuttle-­‐CMV-­‐GOI	  and	  transferred	  to	  a	  chilled	  electroporation	  cuvette	  for	  electroporation	  (200	  Ω,	  2.5	  kV,	  25	  μF).	  The	  cells	  were	  resuspended	  in	  200	  μL	  of	  pre-­‐warmed	  SOC	  medium	  and	  incubated	  in	   a	   bench-­‐top	   shaker	   (37oC,	   500	   rpm)	   for	   1	   hour.	   The	   cultures	   were	   spread	   on	   LB-­‐kanamycin	  agar	  plates	  and	  the	  inverted	  were	  incubated	  overnight	  at	  37oC.	  	  	  








2.5.11 Isolation	  and	  purification	  of	  plasmid	  DNA	  	  Plasmid	  DNA	  was	  isolated	  from	  bacteria	  using	  the	  QIAprep	  Spin	  Miniprep	  Kit	  (Qiagen).	  All	  centrifugation	   steps	   were	   performed	   at	   13000	   rpm	   in	   a	   bench-­‐top	   microcentrifuge.	  Bacterial	  cells	  were	  pelleted	  in	  microcentrifuge	  tubes	  from	  1.5	  mL	  of	  the	  overnight	  culture	  and	  resuspended	   in	  250	  μL	  of	  Buffer	  P1.	  250	  μL	  of	  Buffer	  P2	  and	  350	  μL	  Buffer	  N3	  was	  added	   sequentially	   and	   the	   tubes	   were	   inverted	   several	   times	   after	   each	   addition.	   The	  samples	   were	   centrifuged	   for	   10	   min,	   which	   resulted	   in	   the	   formation	   of	   a	   white	  precipitate	  that	  contained	  cell	  debris.	  The	  supernatant	  was	  transferred	  to	  a	  QIAprep	  spin	  column	  and	   centrifuged	   for	  1	  min.	  The	   flowthrough	  was	  discarded.	   750	  μL	  of	  Buffer	  PE	  was	  added	  to	  the	  upper	  reservoir	  of	   the	  tube	  and	  the	  column	  was	  centrifuged	  for	  1	  min.	  The	  flowthrough	  was	  discarded	  and	  the	  empty	  column	  was	  centrifuged	  again	  for	  1	  min	  to	  remove	  any	  residual	  buffer.	  The	  column	  was	  transferred	  to	  a	  clean	  microcentrifuge	  tube	  and	  50	  μL	  of	  Buffer	  EB	  was	  added.	  The	  column	  was	   left	   to	   stand	   for	  1	  min	  and	  plasmid	  DNA	  was	  eluted	  by	  centrifugation.	  	  	  
2.5.12 Culture	  of	  HEK293	  cells	  	  HEK293	  cells	   in	  modified	  DMEM	  culture	  medium	  were	  maintained	   in	  T75	   flasks	  at	  37oC	  and	   were	   passaged	   twice	   a	   week	   (or	   when	   90%	   confluent).	   The	   culture	   medium	   was	  removed	   and	   the	   cells	   were	   incubated	   with	   1	   mL	   of	   0.5%	   (w/v)	   Trypsin-­‐EDTA	  (Invitrogen),	   to	  detach	   the	   cells	   from	   the	   surface	  of	   the	   flask.	   10	  mL	  of	  modified	  DMEM	  was	  added	  to	  the	  detached	  cells	  and	  1.5	  mL	  of	  the	  resulting	  suspension	  was	  transferred	  to	  a	  new	  T75	  flask	  that	  contained	  13.5	  mL	  of	  modified	  DMEM	  culture	  medium.	  	  








Opti-­‐MEM	   (Life	   Technologies)	   and	   20	   μL	   of	   linearized	   rAd5-­‐GOI.	   The	   solution	   was	  incubated	   for	   10	   min	   at	   RT	   (with	   gentle	   flicking)	   and	   diluted	   with	   600	   μL	   of	   DMEM.	  Finally,	   the	   solution	  was	   added	   drop-­‐wise	   to	   the	   cells	   in	   one	  well.	   The	   transfected	   cells	  were	  maintained	  at	  37oC	  and	  harvested	  when	  cytopathic	  effects,	  including	  the	  rounding	  up	  of	  cells	  and	  their	  detachment	  from	  the	  surface	  of	  well,	  were	  observed.	  The	  expression	  of	  GFP	   was	   determined	   by	   fluorescence	   microscopy,	   to	   monitor	   the	   course	   of	   the	  transfection.	  	  
2.5.14 Amplification	  of	  adenoviruses	  	  Transfected	   HEK293	   cells	   were	   harvested	   2-­‐3	   weeks	   post-­‐transfection,	   when	  approximately	   50%	   of	   the	   cells	   showed	   evidence	   of	   a	   cytopathic	   effect.	   The	   cells	   were	  collected	   in	   culture	   medium	   and	   transferred	   to	   a	   50	   mL	   conical	   centrifuge	   tube.	   Virus	  particles	   were	   released	   from	   the	   cells	   by	   subjecting	   these	   to	   three	   freeze/thaw	   cycles,	  alternating	   the	   tube	  between	   liquid	  nitrogen	  and	  a	  37oC	  water	  bath.	  Cellular	  debris	  was	  collected	  by	   centrifugation	   (10	  min,	  800	  g)	   and	   the	   supernatant,	   containing	   the	  primary	  adenoviral	  stock,	  was	  added	  to	  the	  culture	  medium	  of	  HEK293	  cells	  in	  a	  T75	  flask.	  When	  approximately	  50%	  of	  the	  cells	  showed	  evidence	  of	  a	  cytopathic	  effect	  (2	  or	  3	  days	  post-­‐infection),	   the	  next	  round	  of	  amplification	  was	   initiated.	   In	  the	  final	  round,	  HEK293	  cells	  seeded	   in	   ten	   T175	   flasks	   were	   infected.	   At	   the	   end	   of	   this	   final	   round	   the	   cells	   were	  collected	   in	   media,	   transferred	   to	   50	   mL	   conical	   centrifuge	   flasks	   and	   pelleted	   by	  centrifugation	   (10	   min,	   800	   g).	   The	   supernatants	   were	   removed	   and	   the	   pellets	   were	  combined	   in	   2	  mL	   of	   phosphate	   buffered	   saline	   (PBS).	   Virus	   particles	  were	   released	   by	  subjecting	   the	   cells	   to	   three	   freeze/thaw	   cycles,	   as	   previously	   described.	   Cellular	   debris	  was	   collected	   by	   centrifugation	   (10	   min,	   800	   g)	   and	   the	   adenovirus,	   contained	   in	   the	  supernatant,	  was	  purified	  by	  cesium	  chloride	  (CsCl)	  density	  gradient	  ultracentrifugation,	  as	  described	  in	  section	  2.5.15.	  	  








was	   overlaid	   onto	   the	   gradient	   and	   PBS	  was	   added	   so	   that	   the	   total	   liquid	   volume	  was	  within	  a	  short	  distance	  from	  the	  rim	  of	  the	  tube	  (Figure	  2.5).	  The	  tube	  was	  centrifuged	  at	  20000	  rpm	  for	  2	  h	  at	  20oC	  in	  a	  Beckman	  SW41	  Ti	  swingout	  rotor	  with	  slow	  acceleration	  and	  no	  brake.	  The	  adenovirus	   (at	   the	   interphase	  between	   the	  heavy	  and	   light	  CsCl)	  was	  collected	  in	  a	  5	  mL	  syringe,	  by	  piercing	  the	  tube	  with	  an	  18-­‐gauge	  needle.	  To	  further	  purify	  the	  adenovirus	  and	  remove	  the	  cesium	  chloride,	  the	  solution	  was	  dialyzed	  against	  a	  virus	  dialysis	  buffer	  for	  24	  h	  at	  4oC.	  The	  dialysis	  buffer	  was	  changed	  3-­‐4	  times	  after	  which,	  the	  purified	  adenovirus	  was	  aliquoted	  in	  sterile	  microcentrifuge	  tubes	  and	  stored	  at	  -­‐80oC.	  	  	  	  








	   	  









2.6 Measurement	  of	  PP2A	  activity	  PP2A	  activity	  was	  measured	  using	  the	  PP2A	  Immunoprecipitation	  Phosphatase	  Assay	  Kit	  (Millipore).	  Malachite	   green	   solution,	  malachite	   green	  additive,	   phosphate	   standard,	  Thr	  phospho-­‐peptide	  (K-­‐T-­‐pT-­‐I-­‐R-­‐R),	  PP2A	  catalytic	  subunit	  antibody	  (clone	  1D6)	  and	  protein	  A	  agarose	  beads,	  which	  are	  provided	   in	   the	  kit,	  were	  used	  as	  described	   in	   the	   following	  sections.	  	  	  
2.6.1 Preparation	  of	  malachite	  green	  phosphate	  detection	  solution	  Malachite	  green	  phosphate	  detection	  solution	  was	  prepared	  with	  malachite	  green	  additive	  (solution	  B)	  and	  malachite	  green	  solution	  (solution	  A).	  10	  μL	  of	  solution	  B	  was	  used	  per	  1	  mL	  of	  solution	  A.	  100	  μL	  of	  mixed	  solution	  AB	  was	  used	  per	  well	  of	  a	  96-­‐well	  ½	  volume	  microtitre	  plate.	  	  	  








Table	  2.14	  Preparation	  of	  phosphate	  standards	  	  
2.6.3 Preparation	  of	  the	  Thr	  phospho-­‐peptide	  	  A	   1	   mM	   solution	   of	   the	   Thr	   phospho-­‐peptide	   was	   prepared	   by	   dissolving	   1	   mg	   of	   the	  supplied	  powder	  in	  1.10	  mL	  ddH2O.	  The	  solution	  was	  aliquoted	  and	  stored	  at	  -­‐20oC,	  until	  required.	  	  
2.6.4 PP2A	  immunoprecipitation	  and	  phosphatase	  assay	  
 Immunoprecipitation	  of	  PP2A	  catalytic	  subunits	  2.6.4.1ARVM	  were	  washed	   in	   TBS	   and	   lysed	   in	   cold	   immunoprecipitation	   lysis	   buffer	   (IP	   lysis	  buffer,	  150	  μL	  per	  well).	  Lysates	  were	  collected	  in	  microcentrifuge	  tubes	  and	  clarified	  by	  centrifugation	   (14000	   g,	   5	  min,	   4oC).	   The	   protein	   concentration	   in	   the	   supernatant	  was	  determined	   as	   described	   in	   section	   2.3.1.	   100-­‐200	   μg	   of	   protein	   was	   transferred	   to	   a	  microcentrifuge	   tube	   and	   the	   volume	   was	   adjusted	   to	   500	   μL	   with	   IP	   lysis	   buffer.	   For	  immunoblot	  analysis	  of	  protein	  expression	  in	  the	  pre-­‐IP	  lysate,	  50	  μL	  was	  transferred	  to	  a	  microcentrifuge	   tube	  and	  50	  μL	  of	  2X	  Laemmli	   sample	  buffer	  was	  added.	  PP2A	  catalytic	  subunits	  were	  immunoprecipitated	  from	  the	  remaining	  450	  μL	  of	  lysate	  with	  5	  μg	  of	  PP2A	  catalytic	   subunit	   antibody	   and	   40	   μl	   of	   protein	   A	   agarose	   beads.	   Microcentrifuge	   tubes	  were	   placed	   on	   a	   rotating	   wheel	   for	   2	   h	   at	   4oC.	   Immunocomplexes	   were	   collected	   by	  centrifugation.	  For	  immunoblot	  analysis	  of	  protein	  expression	  in	  the	  post-­‐IP	  supernatant,	  








50	   μL	   of	   the	   supernatant	   was	   transferred	   to	   a	   microcentrifuge	   tube	   and	   50	   μL	   of	   2X	  Laemmli	   sample	   buffer	  was	   added.	   The	   immunocomplexes	  were	  washed	   three	   times	   in	  immunocomplex	  wash	  buffer	  (IC	  wash	  buffer)	  then	  two	  times	  in	  PP2A	  reaction	  buffer.	  	  
 Phosphatase	  assay	  2.6.4.2Immunocomplexes	  were	  incubated	  with	  60	  μl	  of	  1	  mM	  Thr	  phospho-­‐peptide	  and	  20	  μl	  of	  PP2A	   reaction	   buffer	   in	   a	   bench-­‐top	   shaker	   for	   10	   min	   (30oC,	   900	   rpm).	   25	   μl	   of	   the	  reaction	  end-­‐product	  product	  was	  transferred	  to	  wells	  of	  a	  96-­‐well	  ½	  volume	  microtitre	  plate.	  100	  μl	  of	  malachite	  green	  phosphate	  detection	  solution	  was	  added	  and	  colour	  was	  allowed	  to	  develop	  for	  10	  min	  at	  RT.	  Absorbance	  was	  measured	  at	  650	  nm.	  If	  necessary,	  the	   reaction	   end-­‐product	   product	   was	   diluted	  with	   ddH2O	   so	   that	   a	   less-­‐intense	   colour	  response	  was	  obtained	  and	  the	  absorbance	  of	   the	  sample	  was	  within	   the	   linear	  range	  of	  the	  phosphate	  standard	  curve.	  A	  schematic	  overview	  of	  the	  assay	  is	  shown	  in	  Figure	  2.6.	  For	   immunoblot	   analysis	   of	   immunoprecipitated	   PP2A	   catalytic	   subunits,	   40	   μl	   of	   2X	  Laemmli	  sample	  buffer	  was	  added	  to	  the	  pelleted	  beads.	  	  
















	   	  













































Figure	  2.5	  Purification	  of	  adenoviruses	  	  

















3 Expression	  and	  Subcellular	  Distribution	  of	  PP2A	  Subunits	  in	  ARVM	  	  3.1 Introduction	  The	   subcellular	   distribution	   of	   PP2A	   holoenzymes	   is	   governed	   by	   regulatory	   B-­‐type	  subunits.65	  The	  B56	  family	  comprises	  five	  isoforms	  (α,	  β,	  γ,	  δ	  and	  ε);	  γ	  and	  δ	  isoforms	  each	  have	  three	  splice	  variants	  and	  thus,	  B56	  subunits	  are	  the	  largest	  family	  of	  B-­‐type	  subunits.	  Given	   that	   B56	   subunits	   are	   stable	   only	   when	   bound	   to	   the	   PP2A	   core	   enzyme,182	   the	  subcellular	  distribution	  of	  these	  subunits	  reflects	  the	  distribution	  of	  specific	  holoenzymes.	  	  
The	  subcellular	  distribution	  of	  B56α	  and	  B56γ1	  was	  studied	   in	  neonatal	  and	  ARVM	  with	  heterologous	   expression	   of	   HA-­‐tagged	   proteins.111	   Whereas	   immunolabeled	   HA-­‐B56α	  exhibited	   a	   cytosolic	   distribution	  with	   a	   striated	   pattern,	   immunolabeled	  HA-­‐B56γ1	  was	  primarily	  localized	  in	  nuclear	  speckles.111	  These	  differences	  in	  subcellular	  targeting	  result	  from	  small	  domains	  present	  at	  the	  N-­‐	  and	  C-­‐terminus	  of	  B56	  proteins.	  In	  this	  context,	  the	  nuclear	  compartmentalization	  of	  B56γ1	  is	  likely	  to	  result	  from	  a	  nuclear	  localization	  signal	  at	  its	  C-­‐terminus.111	  In	  contrast,	  the	  localization	  of	  B56α	  at	  the	  Z-­‐disc	  and	  M-­‐line	  regions	  is	  mediated	   by	   a	   C-­‐terminal	   residue	   that	   interacts	   with	   the	   spectrin-­‐binding	   domain	   in	  ankyrin-­‐B.119	  	  
The	   subcellular	   distribution	   of	   endogenous	   PP2A	   subunits	   (including	   scaffold,	   catalytic	  and	  regulatory	  B56γ	  and	  B56ε	  subunits)	  was	  recently	  studied	  in	  adult	  mouse	  ventricular	  myocytes.183	   Whereas	   immunolabeled	   PP2A	   scaffold	   and	   catalytic	   subunits	   were	  distributed	   throughout	   the	   cytosol	   and	   nucleus,	   the	   immunolabeled	   regulatory	   subunits	  were	   localized	   to	   discrete	   regions;183	   B56γ	   was	   primarily	   localized	   to	   the	   nucleus	   and	  B56ε	  was	  localized	  to	  the	  Z-­‐disc.183	  	  
















3.2 Objectives	  	  The	  objectives	  of	  the	  studies	  described	  in	  this	  chapter	  were	  to:	  
• Determine	   the	  expression	  of	  PP2A	  scaffold,	  catalytic	  and	  regulatory	  B56	  subunits	   in	  ARVM,	  at	  protein	  level.	  
• Investigate	  the	  subcellular	  distribution	  of	  PP2A	  scaffold,	  catalytic	  and	  regulatory	  B56	  subunits	  in	  unstimulated	  ARVM,	  by	  immunoblot	  analysis	  of	  subcellular	  fractions.	  








3.3 Methods	  3.3.1 ARVM	  isolation,	  culture,	  stimulation	  and	  subcellular	  fractionation	  For	   the	   experiments	   described	   in	   this	   chapter,	   ARVM	  were	   isolated	   from	   the	   hearts	   of	  adult	  male	  Wistar	  rats	  and	  cultured	  as	  described	  in	  the	  Methods	  (sections	  2.1.1	  and	  2.1.2).	  In	  some	  experiments	  the	  cells	  were	  exposed	  to	  vehicle	  or	  10	  nM	  ISO	  for	  10	  min.	  The	  cells	  were	  incubated	  at	  37oC	  for	  the	  duration	  of	  the	  experiment.	  Subcellular	  fractionation	  was	  performed	  as	  described	  in	  the	  Methods	  (section	  2.1.5).	  	  








3.4 Results	  3.4.1 Validation	  of	  ARVM	  subcellular	  fractionation	  	  	  The	  method	  used	  for	  the	  fractionation	  of	  ARVM	  was	  adapted	  from	  a	  previously	  described	  protocol.166	   The	   cultured	   cells	  were	   lysed	   in	   a	   buffer	   that	   contained	  1%	  Triton-­‐X100,	   to	  solubilize	   membranes	   and	   release	   cytosolic	   proteins.	   The	   separation	   of	   soluble	   and	  insoluble	   proteins	  was	   achieved	   by	   centrifugation.	   To	   validate	   the	   fractionation,	   soluble	  and	   insoluble	   fractions	  were	   subjected	   to	   immunoblot	   analysis	   of	   proteins	  with	   known	  subcellular	   compartmentalization.	   Glyceraldehyde	   3-­‐phophate	   dehydrogenase	   (GAPDH)	  and	   the	   α1	   subunit	   of	   the	   NKA	   were	   selected	   as	   markers	   for	   the	   cytosolic	   and	   the	  membrane	   compartment,	   respectively.	   cTnI	   and	   histone	   2B	   (H2B)	   were	   selected	   as	  markers	   for	   the	   myofilament	   and	   the	   nuclear	   compartment,	   respectively.	   As	   expected,	  GAPDH	  and	  α1NKA	  were	  present	  exclusively	  in	  the	  soluble	  fraction	  whereas	  cTnI	  and	  H2B	  appeared	   only	   in	   the	   insoluble	   fraction	   (Figure	   3.2).	   These	   results	   confirmed	   the	  successful	   capture	   of	   cytosolic/membrane	   and	   myofilament/nuclear	   proteins	   in	   the	  soluble	  and	  insoluble	  fraction,	  respectively.	  	  	  	  	  








fractionation	  method	  that	  was	  used,	   it	  appears	  that	  soluble	  proteins	  account	   for	  a	   larger	  proportion	   of	   the	   ARVM	  proteome.	   Taken	   together,	   these	   results	   suggest	   that	   like	  most	  ARVM	  proteins,	  B56α-­‐PP2A	  and	  B56δ-­‐PP2A	  holoenzymes	  are	  relatively	  more	  abundant	  in	  cytosolic/membrane	   (soluble)	   compartments.	   In	   contrast,	   B56γ-­‐PP2A	   holoenzymes	   are	  likely	  to	  exist	  only	  in	  myofilament/nuclear	  (insoluble)	  compartments.	  









Figure	  3.1	  Localization	  of	  B56α	  in	  sarcomere	  	  










































3.5 Discussion	  The	   work	   presented	   in	   this	   chapter	   reveals	   the	   protein	   expression	   and	   subcellular	  distribution	  of	  native	  PP2A	  scaffold,	   catalytic	  and	  regulatory	  B56α,	   -­‐γ	  and	   -­‐δ	  subunits	   in	  ARVM.	   The	   expression	   and	   subcellular	   distribution	   were	   determined	   by	   immunoblot	  analysis	   of	   total	   and	   fractionated	   ARVM	   lysates,	   respectively.	   The	   cells	   were	   lysed	   in	   a	  buffer	   that	   contained	   1%	   Triton-­‐X100	   and	   fractionated	   by	   centrifugation.	   Using	   this	  methodology,	   cytosolic	   and	   membrane	   proteins	   were	   extracted	   in	   the	   soluble	   fraction	  whereas	  myofilament	  and	  nuclear	  proteins	  were	  contained	  in	  the	  insoluble	  fraction.	  	  
Under	   the	   initial	   experimental	   conditions,	   in	  which	   soluble	   and	   insoluble	   proteins	  were	  diluted	  in	  equal	  volumes,	  the	  relative	  abundance	  of	  PP2A	  subunits	  in	  cytosolic/membrane	  and	  myofilament/nuclear	   compartments	  was	   inferred.	  B56γ	  was	  detected	   exclusively	   in	  the	   insoluble	   fraction	   and	   thus,	   consistent	   with	   the	   evidence	   in	   the	   literature,111,183	   in	  ARVM	  this	  regulatory	  subunit	  is	  likely	  to	  target	  PP2A	  holoenzymes	  to	  myofilament	  and/or	  nuclear	   compartments.	   Scaffold,	   catalytic	   and	   regulatory	   B56α	   and	   B56δ	   subunits	  were	  present	   in	   both	   the	   soluble	   (cytosolic/membrane)	   and	   the	   insoluble	  (myofilament/nuclear)	  fraction	  (Figure	  3.3).	  In	  ARVM,	  PP2A	  holoenzymes	  are	  thus	  widely	  distributed	   across	   multiple	   subcellular	   compartments,	   where	   they	   may	   be	   targeted	   to	  specific	  substrates	  by	  distinct	  regulatory	  B56	  subunits.	  	  








this	  subunit	  was	  depleted	  from	  the	  insoluble	  fraction	  and	  enriched	  in	  the	  soluble	  fraction	  of	   ISO-­‐stimulated	   ARVM.	   A	   novel	   observation	   in	   these	   studies	   was	   the	   concomitant	  redistribution	   of	   PP2A	   scaffold	   and	   catalytic	   subunits,	   suggesting	   that	   localization	   of	  B56α-­‐containing	  PP2A	  holoenzymes	  is	  subject	  to	  β-­‐adrenergic	  regulation	  (Figure	  3.4).	  	  
Surprising	   at	   first,	   the	   depletion	   of	   subunits	   from	   the	   insoluble	   fraction	  was	   significant	  whilst	   the	   enrichment	   in	   the	   soluble	   fraction	   was	   not	   significant.	   Nevertheless,	   these	  results	  can	  be	  justified	  by	  considering	  the	  basal	  subcellular	  distribution	  of	  these	  subunits.	  Scaffold,	   catalytic	   and	   B56α	   subunits	   were	   markedly	   more	   abundant	   in	   the	   soluble	  fraction	   relative	   to	   the	   insoluble	   fraction.	   Therefore,	   what	   appears	   to	   be	   a	   small	   (not	  significant)	   proportional	   increase	   in	   the	   soluble	   fraction	   may	   represent	   a	   large	  (significant)	  proportional	  decrease	  in	  the	  insoluble	  fraction.	  	  








4 β-­‐Adrenergic	  Regulation	  of	  B56δ	  Phosphorylation	  in	  ARVM	  4.1 Introduction	  The	  human	  gene	  encoding	  the	  PP2A	  regulatory	  B56δ	  subunit	  (i.e.	  PPP2R5D)	  is	  localized	  on	  chromosome	   region	   6p21.1	   and	   gives	   rise	   to	   three	   N-­‐terminal	   splice	   variants	   through	  alternative	   splicing.117,184,185	  With	   602	   amino	   acids	   and	   a	   predicted	  molecular	   weight	   of	  69,999	  Da	  (i.e.	  70	  kDa)	  δ1	  is	  the	  longest	  splice	  variant.	  Relative	  to	  this	  splice	  variant,	  δ2	  and	  δ3	  lack	  amino	  acids	  84-­‐115	  and	  1-­‐115,	  respectively.	  	  	  
Five	  consensus	  PKA	  phosphorylation	  sites	  were	   identified	   in	  the	  amino	  acid	  sequence	  of	  δ1.12	   In	   vitro,	   PKA	   phosphorylates	   only	   four	   sites	   (S60,	   S75,	   S88	   and	   S573)	   and	   the	  phosphorylation	   of	   these	   stimulates	   the	   dephosphorylation	   of	   substrate	   proteins	   by	   the	  pertinent	   holoenzyme.114,186	   In	   HEK293	   cells,	   the	   heterologously-­‐expressed	   protein	   is	  phosphorylated	  primarily	  at	  S573	  (and	  only	  slightly	  at	  S88)	  following	  the	  incubation	  of	  the	  cells	   with	   the	   cAMP	   analogue	   dibutyryl	   cAMP.114	   Importantly,	   in	   vitro	   and	   in	   cells,	   the	  phosphorylation	  at	  S573	  is	  necessary	  and	  sufficient	  to	  activate	  the	  holoenzyme.114	  	  	  	  








4.2 Objectives	  The	  objectives	  of	  the	  studies	  described	  in	  this	  chapter	  were	  to:	  
• Determine	  if	  stimulation	  with	  ISO	  induces	  the	  phosphorylation	  of	  B56δ	  in	  ARVM	  and	  the	  dose-­‐	  and	  time-­‐dependence	  of	  the	  response.	  
• Determine	  the	  relative	  contribution	  of	  β1-­‐	  and	  β2-­‐ARs	  to	  ISO-­‐induced	  phosphorylation	  of	  B56δ.	  	  
• Determine	  the	  role	  of	  PKA,	  as	  a	  downstream	  mediator	  of	  B56δ	  phosphorylation.	  








4.3 Methods	  4.3.1 ARVM	  isolation,	  culture	  and	  pharmacological	  treatment	  	  For	   the	   experiments	   described	   in	   this	   chapter,	   ARVM	  were	   isolated	   from	   the	   hearts	   of	  adult	  male	  Wistar	  rats	  and	  cultured	  as	  described	  in	  the	  Methods	  (sections	  2.1.1	  and	  2.1.2).	  The	  cells	  were	  exposed	  to	  vehicle	  or	  ISO	  (1-­‐100	  nM)	  for	  2-­‐60	  min.	  Propranolol	  (100	  nM),	  CGP	  20712A	  (100	  nM),	  ICI	  118,551	  (100	  nM)	  or	  the	  appropriate	  vehicle	  was	  added	  10	  min	  before	   incubation	  with	   ISO.	  H89	   (2-­‐10	  μM),	  myr-­‐PKI	   (10	  μM)	  or	   the	  appropriate	  vehicle	  was	  added	  30	  min	  before	   incubation	  with	   ISO.	  The	  cells	  were	  exposed	   to	  N6-­‐Benz-­‐cAMP	  (100-­‐500	   μM)	   for	   30	  min.	   Details	   of	   the	   compounds	   used	   are	   provided	   in	   the	  Methods	  (Table	   2.1).	   The	   cells	  were	  maintained	   at	   37oC	   for	   the	  duration	  of	   the	   treatment(s).	   For	  immunoblot	  analysis,	   the	   cells	  were	  harvested	   in	  2X	  Laemmli	   sample	  buffer	   (200	  μl	  per	  well).	  
4.3.2 Mouse	  heart	  samples	  Flash-­‐frozen	  hearts	   from	  homozygous	  B56δ	  KO	  and	  WT	   littermate	  mice	  were	  a	  kind	  gift	  from	  Veerle	  Janssens	  (KU	  Leuven,	  Belgium).120	  Heart	  samples	  were	  prepared	  as	  described	  in	   the	  Methods	   (section	   2.2).	   Samples	   of	   unstimulated	   and	   ISO-­‐stimulated	  WT	  C57/BL6	  mouse	  hearts	  were	  kindly	  provided	  by	  Dr.	  Karen	  Aughton	   (King’s	  College,	  London).	  The	  hearts	  were	  perfused	  in	  the	  Langendorff	  mode	  with	  Krebs	  solution	  for	  10	  min,	  then	  with	  Krebs	  solution	  ±	  10	  nM	  ISO	  for	  a	  further	  10	  min.	  	  	  	  	  	  








 	  Principles	  of	  Phos-­‐tagTM	  SDS-­‐PAGE	  4.3.3.1The	   principles	   of	   Phos-­‐tagTM	   SDS-­‐PAGE	   are	   shown	   schematically	   in	   Figure	   4.1.	   When	  associated	  with	  two	  divalent	  manganese	   ions	  (Mn2+),	   the	  acrylamide-­‐pendant	  Phos-­‐tagTM	  reagent	  binds	  phospho-­‐monoester	  dianions	  on	  Ser,	  Thr	  and	  Tyr	  residues.188	  The	  migration	  of	  a	  protein	  through	  a	  Phos-­‐tagTM	  gel	  therefore	  depends	  on	  its	  phosphorylation	  status;	  the	  more	  phosphorylated	  a	  protein	   is,	   the	   slower	   it	  will	  migrate	   through	   the	  gel.	   If	  multiple	  phospho-­‐species	  of	  a	  particular	  protein	  are	  present	  within	  a	  sample,	  immunoblot	  analysis	  will	  reveal	  bands	  with	  distinct	  migration	  profiles.	  The	  slower	  migrating	  bands	  will	  contain	  the	  more-­‐phosphorylated	  species	  whereas	  the	  faster	  migrating	  bands	  will	  contain	  the	  less-­‐phosphorylated	  species.	  	  








4.4 Results	  4.4.1 Validation	  of	  a	  B56δ	  antibody	  	  Immunoblot	   analysis	   of	   cardiac	   B56δ	   was	   performed	   with	   an	   affinity-­‐purified	   rabbit	  polyclonal	  antibody	  raised	  against	  a	  peptide	  comprising	  residues	  552	  and	  602	  of	  human	  B56δ	   (UniProt	  entry	  Q14738).	   Importantly,	   as	   shown	   in	  Figure	  4.2,	   the	   sequence	  of	   this	  peptide	  is	  conserved	  in	  rat	  and	  mouse	  isoforms.	  To	  confirm	  the	  specificity	  of	  the	  antibody,	  ARVM	   samples	  were	   probed	   in	   parallel	  with	   heart	   samples	   of	   littermate	  WT	   and	   global	  B56δ	  KO	  mice.	  As	   shown	   in	  Figure	  4.3,	   in	  both	  ARVM	  and	  WT	  mouse	  heart	   samples	   the	  antibody	   primarily	   detected	   a	   protein	   whose	   apparent	   molecular	   weight	   was	   ~70-­‐kDa	  (band	   A).	   Additional	   weaker	   bands	   (B	   in	   ARVM;	   B	   and	   C	   in	   WT	   mouse	   heart)	   were	  observed	  at	  smaller	  molecular	  weights.	  Relative	  to	  A,	   the	   intensity	  of	  bands	  B	  and	  C	  was	  markedly	   lower	   and	   in	   ARVM,	   band	   B	   was	   detected	   only	   when	   the	   largest	   volume	   of	  sample	  was	   loaded	   and	   the	   film	  was	   exposed	   to	   the	   ECL	   signal	   for	   longer.	   None	   of	   the	  proteins	  detected	  by	  the	  antibody	  in	  ARVM	  and	  in	  the	  WT	  mouse	  heart	  were	  detected	  in	  the	  KO	  mouse	  heart.	   This	   indicated	   that	   in	   the	   former	   samples	   the	   antibody	   specifically	  and	  exclusively	  detected	  B56δ,	  whose	  full-­‐length	  variant	  is	  predicted	  to	  have	  a	  molecular	  weight	  of	  72-­‐kDa	  in	  the	  rat.	  	  	  








in	  section	  4.4.1.	  As	  shown	  in	  Figure	  4.4	  (panel	  A),	  in	  ISO-­‐stimulated	  cells	  the	  predominant	  B56δ	   species	  migrated	  more	   slowly	   than	   in	   cells	   exposed	   to	   vehicle.	   These	   results	   thus	  indicated	   that	   ISO	   increased	   the	   phosphorylation	   of	   B56δ.	   Samples	   were	   additionally	  resolved	  by	  standard	  SDS-­‐PAGE.	  As	  shown	   in	  Figure	  4.4	   (panel	  B),	   in	   the	  absence	  of	   the	  Phos-­‐tagTM	  reagent	  and	  using	  the	  same	  antibody	  for	  detection,	  B56δ	  protein	  displayed	  an	  identical	   migration	   profile	   in	   both	   treatment	   groups	   and	   no	   additional	   bands	   were	  observed.	  	  
4.4.3 ISO-­‐induced	  phosphorylation	  of	  B56δ	  at	  S573	  	  Based	  on	  the	  evidence	  that	  in	  primary	  (non-­‐cardiac)	  cells	  B56δ	  is	  phosphorylated	  by	  PKA	  at	  S573,114	  the	  phosphorylation	  of	  this	  site	  was	  investigated	  by	  immunoblot	  analysis	  with	  a	  phospho-­‐specific	  antibody	  that	  recognizes	  B56δ	  phosphorylated	  at	  S573,	  a	  kind	  gift	  from	  Angus	   Nairn	   (The	   Rockefeller	   University,	   NY).114	   This	   corresponds	   to	   S593	   in	   the	   rat	  sequence	  (Figure	  4.2).	  To	  get	  an	   indication	  as	   to	  whether	   the	  antibody	  detected	  B56δ	   in	  ARVM,	   in	   the	   first	   experiment	   samples	   of	   unstimulated	   and	   ISO-­‐stimulated	   ARVM	  were	  loaded	   in	  duplicate	  on	  one	  gel	  and	  proteins	  were	   transferred	   to	  a	  single	  membrane	   that	  was	  cut	   into	   two	  halves	  before	   immunoblot	  analysis.	  One	  half	  was	  probed	  with	   the	   total	  B56δ	   antibody	   and	   the	   other	   half	   was	   probed	   with	   the	   phospho-­‐specific	   antibody.	   As	  shown	  in	  Figure	  4.5	  (panel	  A),	  the	  latter	  antibody	  detected	  a	  protein	  at	  the	  same	  molecular	  weight	  as	  the	  protein	  that	  was	  detected	  by	  the	  total	  B56δ	  antibody	  (~70-­‐kDa,	  indicated	  by	  the	  arrow),	  suggesting	  that	  it	  recognized	  B56δ.	  Furthermore,	  the	  affinity	  of	  the	  phospho-­‐specific	  antibody	  for	  B56δ	  was	  increased	  dramatically	  following	  stimulation	  of	  ARVM	  with	  ISO,	   as	   shown	  by	   the	   increased	   intensity	  of	   the	   signal	   in	   this	   sample.	  These	   results	   thus	  indicated	  that	  in	  ARVM	  B56δ	  is	  phosphorylated	  at	  S573	  in	  response	  to	  ISO	  stimulation.	  	  








the	   ~70	   kDa	   protein	   that	   was	   detected	   in	   ARVM	   by	   the	   pS573	   antibody	   (and	   whose	  phosphorylation	  was	  increased	  by	  treatment	  with	  ISO)	  was	  detected	  also	  in	  the	  WT	  mouse	  heart,	   but	   not	   in	   the	   KO	   mouse	   heart.	   This	   provided	   confirmation	   that	   in	   ARVM	   the	  antibody	   detected	   B56δ	   phosphorylated	   at	   S573.	   The	   protein	   that	   was	   detected	   by	   the	  antibody	  above	  the	  75-­‐kDa	  marker	  in	  ARVM	  was	  detected	  in	  both	  the	  WT	  and	  in	  the	  B56δ	  KO	  mouse	   heart.	   This	   confirmed	   that	   it	  was	   not	   an	   isoform	  of	   B56δ	   and	   that	   the	   signal	  resulted	  from	  non-­‐specific	  binding	  of	  the	  antibody	  to	  an	  unidentified	  cardiac	  protein.	  
In	   further	   studies	   B56δ	   phosphorylation	   was	   determined	   at	   S573	   in	   samples	   of	  unstimulated	   and	   ISO-­‐stimulated	   WT	   mouse	   hearts	   perfused	   in	   the	   Langendorff	   mode.	  These	  samples	  were	  probed	  in	  parallel	  with	  samples	  of	  unstimulated	  and	  ISO-­‐stimulated	  ARVM;	   the	   results	   showed	   that	   ISO	   induces	   B56δ	   phosphorylation	   at	   S573	   in	   isolated	  cardiac	  cells	  and	  hearts	  (Figure	  4.5,	  panel	  C).	  	  
4.4.4 Dose-­‐	  and	  time-­‐response	  profiles	  of	  ISO-­‐induced	  phosphorylation	  of	  B56δ	  at	  S573	  Having	  shown	  that	  the	  phosphorylation	  of	  B56δ	  was	  increased	  at	  S573	  in	  ARVM	  exposed	  to	  10	  nM	  ISO	  for	  10	  min,	  in	  subsequent	  studies	  the	  dose-­‐	  and	  time-­‐response	  profiles	  were	  determined.	  In	  dose-­‐response	  studies,	  the	  cells	  were	  stimulated	  with	  1,	  10	  or	  100	  nM	  ISO.	  As	   shown	   in	   Figure	   4.6	   (panel	   A),	   the	   ISO-­‐induced	   phosphorylation	   of	   S573	   was	   dose-­‐dependent	  and	  was	  increased	  significantly	  by	  stimulation	  with	  a	  concentration	  of	  ISO	  that	  was	  ≥	  10	  nM.	  In	  time-­‐response	  studies	  the	  cells	  were	  exposed	  to	  10	  nM	  ISO	  for	  2-­‐60	  min.	  As	  shown	  in	  Figure	  4.6	  (panel	  B),	  maximal	  phosphorylation	  of	  S573	  occurred	  within	  2	  min	  and	  the	  response	  was	  sustained	  for	  at	  least	  60	  min.	  	  	  	  	  	  








antagonist	  ISO	  did	  not	  cause	  an	  increase	  in	  phosphorylation	  of	  S573,	  confirming	  that	  ISO	  induced	   the	  phosphorylation	  of	   the	   site	   by	   stimulating	  β-­‐ARs.	  To	  determine	   the	   relative	  contributions	  of	  β1-­‐	  and	  β2-­‐ARs,	   ISO-­‐induced	  phosphorylation	  of	  S573	  was	  determined	  in	  the	   absence	  and	  presence	  of	   the	   selective	  β1-­‐AR	  antagonist	  CGP	  20712A	   (CGP)189	   or	   the	  selective	   β2-­‐AR	   antagonist	   ICI	   118,551	   (ICI).190	   As	   shown	   in	   Figure	   4.7	   (panel	   A),	   CGP	  abolished	   ISO-­‐induced	  phosphorylation	   of	   S573.	   In	   contrast,	   ICI	   partially	   attenuated	   the	  response.	  In	  complementary	  work,	  the	  phosphorylation	  of	  cTnI	  at	  S23/24	  was	  determined	  by	   immunoblot	   analysis	   in	   the	   same	   samples.	   As	   shown	   in	   Figure	   4.7	   (panel	   B),	   ISO	  induced	  the	  phosphorylation	  of	  cTnI	  at	  S23/24.	  As	  expected,	  the	  response	  was	  abolished	  by	  propranolol.	  The	  response	  was	  abolished	  also	  by	  CGP	  but	  was	  unchanged	  by	  ICI.	  	  








through	  different	  mechanisms,	  suggesting	  therefore	  that	  PKA	  activity	  is	  necessary	  for	  the	  response.	   To	   determine	   if	   PKA	   activation	   is	   sufficient	   for	   the	   response,	   the	  phosphorylation	   of	   the	   site	   was	   determined	   in	   ARVM	   exposed	   to	   N6-­‐Benz-­‐cAMP,	   a	  membrane-­‐permeant	  PKA-­‐selective	  cAMP	  analog.192	  As	  shown	  in	  Figure	  4.8	  (panel	  C),	  with	  increasing	   concentrations	   of	   N6-­‐Benz-­‐cAMP	   (100,	   250	   or	   500	   μM)	   a	   dose-­‐dependent	  increase	  in	  the	  phosphorylation	  of	  S573	  was	  observed.	  As	  also	  shown	  in	  Figure	  4.8	  (panel	  C),	  similar	  increases	  in	  phosphorylation	  of	  cTnI	  at	  S23/24	  were	  observed.	  	  









Figure	  4.1	  Principles	  of	  Phos-­‐tagTM	  SDS-­‐PAGE	  	  



























Figure	   4.4	   Investigating	   ISO-­‐induced	   phosphorylation	   of	   B56δ	   by	   Phos-­‐tagTM	   SDS-­‐


















Figure	  4.6	  Dose-­‐	  and	  time-­‐response	  profiles	  of	  ISO-­‐induced	  phosphorylation	  of	  B56δ	  
at	  S573	  




























































4.5 Discussion	  The	   work	   presented	   in	   this	   chapter	   shows	   β-­‐adrenergic	   regulation	   of	   B56δ	  phosphorylation	   in	  ARVM	  and	  mouse	  heart.	  The	  expression	  of	  B56δ	  was	  determined	  by	  immunoblot	  analysis	  with	  an	  antibody	  that	  recognizes	  a	  sequence	  at	  the	  C-­‐terminus	  of	  the	  human	  protein,	  which	   is	  also	  present	   in	   rat	  and	  mouse	   isoforms.	   In	  ARVM	  this	  antibody	  detected	   a	   protein	   whose	   apparent	   molecular	   weight	   corresponded	   to	   the	   predicted	  molecular	  weight	  of	  full-­‐length	  rat	  B56δ	  (i.e.	  72-­‐kDa).	  Importantly,	  all	  proteins	  that	  were	  detected	   in	  ARVM	  and	   in	   the	  WT	  mouse	  heart	  were	  not	  detected	   in	   the	  B56δ	  KO	  mouse	  heart,	  indicating	  that	  the	  antibody	  specifically	  and	  exclusively	  detected	  B56δ	  (Figure	  4.3).	  	  
The	  three	  splice	  variants	  of	  human	  B56δ	  differ	  at	  the	  N-­‐terminus.184,185	  The	  sequence	  that	  is	   recognized	   by	   the	   B56δ	   antibody,	   at	   the	   C-­‐terminus	   of	   δ1,	   is	   conserved	   in	   δ2	   and	   δ3.	  Therefore,	  if	  additional	  (N-­‐terminal)	  splice	  variants	  of	  B56δ	  had	  been	  expressed	  in	  ARVM,	  these	   would	   have	   been	   detected.	   However,	   immunoblots	   of	   B56δ	   suggest	   that	   only	   the	  full-­‐length	   (72-­‐kDa)	   variant	   is	   expressed	   in	   ARVM	   at	   protein	   level.	   Nevertheless,	   the	  possibility	   that	   additional	   splice	   variants	   are	   expressed	   at	   levels	   that	   are	   below	   the	  antibody’s	   limit	   of	   detection	   cannot	   be	   excluded.	   Related	   to	   this,	   in	   the	   sample	   of	   WT	  mouse	  heart,	  which	  contained	  more	  protein,	  multiple	  proteins,	   likely	  to	  have	  been	  splice	  variants	  of	  B56δ,	  were	  detected.	  	  








a	  particular	  protein.193	  In	  this	  instance,	  due	  to	  a	  lack	  of	  better	  sample	  resolution,	  it	  was	  not	  possible	  to	  determine	  whether	  B56δ	  is	  phosphorylated	  at	  multiple	  sites	  in	  ARVM.	  	  
Further	   studies	   of	   the	   specific	   site	   of	   phosphorylation	  were	   guided	   by	   evidence	   that	   in	  primary	  cells	  PKA,	  activated	  downstream	  of	  Gαs	  GPCRs,	  phosphorylates	  B56δ	  at	  S573.114	  By	   using	   an	   antibody	   that	   detects	   B56δ	   phosphorylated	   at	   S573,	   increased	  phosphorylation	   of	   this	   site	  was	   observed	   in	   ARVM	   exposed	   to	   physiologically	   relevant	  concentrations	  of	  the	  β-­‐AR	  agonist	  ISO	  (Figure	  4.5).	  Although	  its	  relevance	  is	  beyond	  the	  scope	   of	   this	   discussion,	   the	   phospho-­‐specific	   antibody	   (raised	   against	   the	   phospho-­‐peptide	  LRRKpSELPQ,	  Figure	  4.2)	   recognized	  an	  additional	  protein	   in	  ARVM	  and	  mouse	  hearts.	   Based	   on	   the	   strong	   intensity	   of	   the	   signal	   that	   resulted	   from	   its	   detection,	   this	  protein	  is	  likely	  to	  be	  maximally	  phosphorylated	  under	  basal	  conditions.	  	  








To	   study	   the	   role	  of	  PKA	   in	   ISO-­‐induced	  phosphorylation	  of	  B56δ	  at	   S573	   this	   response	  was	  determined	  in	  the	  absence	  and	  presence	  of	  the	  PKA	  inhibitor	  H89.	  The	  concentration	  of	  H89	  that	  has	  been	  used	  to	  inhibit	  PKA	  in	  ARVM	  is	  10	  μM196,197	  and	  indeed,	  a	  significant	  reduction	  in	  phosphorylation	  of	  B56δ	  at	  S573	  was	  attained	  by	  using	  the	  inhibitor	  at	  such	  concentration.	   However,	   H89	   is	   non-­‐selective	   and	   many	   off-­‐targeted	   effects	   have	   been	  described.198,199	   Importantly,	  antagonistic	  activity	  at	  β1-­‐	  and	  β2-­‐ARs	  has	  been	  reported.200	  Therefore,	   an	   alternative	   inhibitor	   of	   PKA	   (myr-­‐PKI)	   was	   used.	   The	   results	   from	   these	  complementary	   studies	   showed	   that	   by	   inhibiting	   PKA,	   the	   increase	   in	   B56δ	  phosphorylation	  at	  S573	  was	  attenuated.	  The	  phosphorylation	  of	  cTnI	  at	  the	  sites	  that	  are	  phosphorylated	  by	  PKA	   in	  β-­‐adrenergic	  signaling	  (S23/24)47	  was	  determined	  as	  readout	  of	   PKA	   activity.	   As	   expected,	   the	   ISO-­‐induced	   increase	   in	   cTnI	   phosphorylation	   was	  blunted	  in	  the	  presence	  of	  myr-­‐PKI.	  Importantly,	  the	  increase	  in	  phosphorylation	  of	  cTnI	  (S23/24)	   and	   B56δ	   (S573)	   was	   blunted	   by	   a	   similar	   magnitude,	   indicating	   that	   the	  observed	   reduction	   in	   phosphorylation	   of	   B56δ	   reflected	   maximal	   PKA	   inhibition.	   In	  parallel	   studies	   the	   effect	   of	   direct	   PKA	   activation	   on	   B56δ	   S573	   phosphorylation	   was	  explored.	  By	  using	  N6-­‐Benz-­‐cAMP	  to	  activate	  PKA,	  phosphorylation	  of	  B56δ	  at	  S573	  was	  increased.	   Taken	   together,	   these	   data	   showed	   that	   in	   ARVM	   PKA	   is	   necessary	   and	  sufficient	   for	   the	   phosphorylation	   of	   B56δ	   at	   S573	   downstream	   of	   stimulated	   β-­‐ARs	  (Figure	  4.8).	  	  
















5 Construction	  and	  Characterization	  of	  Novel	  Adenoviral	  Vectors	  5.1 Introduction	  The	   studies	   in	   the	   previous	   chapter	   revealed	   that	   in	   cardiac	   cells	   endogenous	   B56δ	   is	  phosphorylated	  at	  S573	  by	  PKA,	  primarily	  downstream	  of	  stimulated	  β1-­‐ARs.	  In	  vitro	  and	  in	   transfected	  HEK293	  cells,	   the	  phosphorylation	  of	  B56δ	  at	  S573	  by	  PKA	  stimulates	  the	  activity	   of	   the	   associated	   catalytic	   subunit,	   inducing	   dephosphorylation	   of	   substrate	  proteins.114,186	  Although	  it	  may	  be	  predicted	  that	  also	  in	  cardiac	  cells	  the	  phosphorylation	  of	  B56δ	  at	  S573	  would	   lead	  to	   increased	  activity	  of	  B56δ-­‐containing	  PP2A,	  the	   impact	  of	  such	   phosphorylation	   on	   the	   subcellular	   localization	   of	   the	   holoenzyme,	   protein	  phosphorylation	  and	  function	  in	  β-­‐adrenergic	  signaling	  is	  unknown.	  	  
The	   functional	   role	   of	   B56δ	   S573	  phosphorylation	   in	  vivo	   has	   thus	   far	   been	  determined	  only	   in	   the	  mouse	   striatum.114	   In	   these	   studies	   flag-­‐tagged	  B56δ	   in	  WT	   or	   quad-­‐mutant	  (non-­‐phosphorylatable	  form)	  was	  heterologously	  expressed	  in	  striatal	  neurons	  by	  adeno-­‐associated	  virus-­‐mediated	  gene	  transfer.114	  In	  vivo	  endogenous	  B56δ	  is	  phosphorylated	  by	  PKA	  only	  at	  S573;114	  nevertheless,	  in	  the	  heterologous	  non-­‐phosphorylatable	  protein	  S60,	  S75	   and	   S88,	   which	   are	   phosphorylated	   by	   PKA	   in	   vitro,	   were	   also	   rendered	   non-­‐phosphorylatable.114	  	  
Determination	  of	   the	   role	   of	  B56δ	  phosphorylation	   at	   S573	   in	   cardiac	   cells	   requires	   the	  expression	   of	   a	   B56δ	   variant	   that	   has	   been	   rendered	   non-­‐phosphorylatable	   through	   a	  single	  amino	  acid	  substitution	  (S573A).	  The	  work	  described	  in	  this	  chapter	  describes	  the	  construction	   and	   characterization	   of	   novel	   adenoviral	   vectors	   to	   allow	   the	   heterologous	  expression	  of	  B56δ	  in	  WT	  or	  non-­‐phosphorylatable	  form	  in	  ARVM.	  	  	  	  	  








5.2 Objectives	  The	  objectives	  of	  the	  studies	  described	  in	  this	  chapter	  were	  to:	  
• Construct	   adenoviral	   vectors	   that	   express	   GFP-­‐tagged	   human	   B56δ	   in	  WT	   or	   non-­‐phosphorylatable	   (S573A)	   form,	   referred	   to	   as	   AdV.GFP-­‐B56δ-­‐WT	   and	   AdV.GFP-­‐B56δ-­‐SA,	  respectively.	  	  
• Determine	   expression	   and	   ISO-­‐induced	   phosphorylation	   of	   GFP-­‐B56δ-­‐WT	   and	   GFP-­‐B56δ-­‐SA	  at	  S573A	  in	  ARVM.	  








5.3 Methods	  5.3.1 Construction	  of	  adenoviral	  vectors	  
 Principles	  of	  the	  AdEasy	  system	  5.3.1.1The	   construction	   of	   replication-­‐defective	   adenoviral	   vectors	   using	   the	   AdEasy	   system	  involves	  (i)	  cloning	  a	  GOI	  into	  one	  of	  four	  shuttle	  vectors	  and	  (ii)	  transferring	  the	  GOI	  into	  the	  adenovirus	  genome;	  typically	  the	  human	  AdV	  genome,	  lacking	  the	  E1	  and	  E3	  genes.202	  The	   recombinant	   shuttle	   vector	   is	   linearized	   with	   PmeI	   and	   transformed	   into	   E.	   coli	  BJ5183	   cells,	  which	   contain	   the	   adenoviral	   backbone	   plasmid	   pAdEasy-­‐1.	   In	   these	   cells,	  recombinant	  adenoviral	  DNA	  (rAd-­‐GOI)	   is	  generated	  by	  homologous	  recombination.	  The	  transformed	   cells	   are	   selected	   for	   kanamycin	   resistance	   (provided	  by	   the	   shuttle	   vector	  DNA)	  and	  recombinants	  are	  identified	  by	  digestion	  with	  appropriate	  restriction	  enzymes.	  rAd-­‐GOI	   is	   linearized	   with	   PacI,	   to	   expose	   the	   inverted	   terminal	   repeats	   (ITR),	   and	  transfected	   into	   HEK293	   cells.	   These	   express	   recombinant	   adenovirus	   E1	   and	   can	   thus	  amplify	   adenoviral	   DNA	   that	   lacks	   the	   E1	   gene.202	   A	   schematic	   overview	   of	   the	   AdEasy	  system	  is	  provided	  in	  Figure	  5.1.	  








PmeI	   and	   transformed	   into	   E.coli	  BJ5183-­‐AD-­‐1	   electrocompetent	   cells,	   for	   homologous	  recombination	   with	   pAdEasy-­‐1.	   Well-­‐isolated	   small	   colonies,	   which	   are	   most	   likely	   to	  contain	  recombinant	  adenoviral	  DNA	  (rAd-­‐GOI),	  were	   inoculated	   into	  LB-­‐kanamycin	  and	  mini-­‐preps	   were	   performed	   to	   isolate	   plasmid	   DNA.	   To	   confirm	   that	   homologous	  recombination	   had	   occurred,	   the	   size	   of	   the	   supercoiled	   DNA	   was	   checked	   by	  electrophoresis	  on	  a	  0.8%	  TAE	  gel.	  Candidate	  recombinants,	  which	  yielded	  a	  product	  that	  was	   larger	   than	   the	   12	   kb	   marker,	   were	   validated	   by	   digestion	   with	   PacI.	   True	  recombinants,	  which	   yielded	   a	   4.5	   or	   3	   kb	   product	   and	   a	   product	   >	   30	   kb	   (Figure	   5.4),	  were	  transformed	  into	  DH5α	  cells	  and	  mini-­‐preps	  were	  performed	  to	  isolate	  plasmid	  DNA.	  For	   packaging	   of	   the	   adenovirus	   particles,	   PacI-­‐digested	   rAd5-­‐GOI	   was	   transfected	   into	  HEK293	  cells.	  These	  were	  maintained	  at	  37oC	  and	  harvested	  when	  significant	  cytopathic	  effects	  (and	  expression	  of	  GFP)	  were	  observed.	  The	  adenovirus	  was	  amplified	  in	  the	  same	  cell	   line	   and	  purified	  by	  CsCl	  density	   gradient	  ultracentrifugation.	  The	   infectious	   titer	  of	  the	  purified	  adenoviruses	  was	  determined	  by	  performing	  the	  TCID50	  assay.	  Titers	  of	  3.2	  x	  109	  and	  2.18	  x	  1010	  PFU/mL	  were	  obtained	  for	  AdV.GFP-­‐B56δ-­‐WT	  and	  AdV.GFP-­‐B56δ-­‐SA,	  respectively.	  
5.3.2 	  ARVM	  isolation,	  culture,	  infection	  with	  adenoviruses	  and	  stimulation	  For	   the	   experiments	   described	   in	   this	   chapter,	   ARVM	  were	   isolated	   from	   the	   hearts	   of	  adult	  male	  Wistar	  rats	  and	  cultured	  as	  described	  in	  the	  Methods	  (sections	  2.1.1	  and	  2.1.2).	  However,	   in	   some	   experiments	   the	   cells	   were	  maintained	   in	   culture	   for	   42	   h.	   Infection	  with	  adenoviral	  vectors	  was	  performed	  as	  described	  in	  the	  Methods	  (section	  2.1.3).	  ARVM	  were	  exposed	  to	  vehicle	  or	  10	  nM	  ISO	  (10	  min,	  37oC)	  18	  h	  post-­‐infection.	  For	  immunoblot	  analysis	   of	   protein	   expression	   and	   phosphorylation	   the	   cells	   were	   harvested	   in	   2X	  Laemmli	  sample	  buffer	  (200	  μl	  per	  well).	  	  
















5.4 Results	  Although	  the	  initial	  objective	  was	  to	  characterize	  expression	  of	  GFP-­‐tagged	  WT	  and	  S573A	  B56δ	  in	  parallel,	  this	  was	  prevented	  by	  difficulties	  encountered	  in	  constructing	  AdV.GFP-­‐B56δ-­‐SA.	  Thus,	  whilst	  the	  construction	  of	  this	  adenoviral	  vector	  was	  re-­‐attempted,	  studies	  were	  begun	  with	  AdV.GFP-­‐B56δ-­‐WT.	  	  	  	  








To	  further	  characterize	  the	  adenoviral	  vector	  the	  expression	  of	  non-­‐B56δ	  PP2A	  subunits	  (i.e.	  scaffold,	  catalytic	  and	  regulatory	  B56α	  and	  -­‐γ	  subunits)	  was	  determined.	  As	  shown	  in	  Figure	   5.6	   (panel	   A),	   the	   expression	   of	   scaffold	   subunits	   was	   similar	   in	   all	   samples,	  including	  uninfected	   cells.	  The	  expression	  of	   catalytic	   subunits,	  however,	   increased	  with	  increasing	  MOI	   in	   the	   first	  18	  h	  of	   infection.	  At	   the	  42-­‐hour	   time	  point,	   their	   expression	  was	  similarly	  elevated	  in	  all	  samples	  of	  infected	  cells.	  As	  also	  shown	  in	  Figure	  5.6	  (panel	  C),	   the	  expression	  of	  B56α	  was	  reduced	  at	  42	  h	  post-­‐infection	  with	  a	  MOI	  that	  was	  ≥	  30.	  The	  expression	  of	  B56γ,	  however,	  was	  unchanged	  (Figure	  5.6,	  panel	  D).	  	  
To	   determine	   whether	   the	   increased	   expression	   of	   catalytic	   subunits	   is	   driven	   by	   the	  heterologous	   expression	   of	   B56δ,	   the	   expression	   of	   catalytic	   subunits	   was	   compared	  between	   ARVM	   that	   expressed	   either	   GFP-­‐B56δ-­‐WT	   or	   GFP.	   The	   adenovirus	   that	  expresses	  GFP	  (i.e.	  AdV.GFP)	  was	  used	  at	  MOI	  10	  and	   the	  reason	   for	   this	   is	  explained	   in	  Chapter	  7.	  As	  shown	  in	  Figure	  5.7,	  the	  relative	  increase	  in	  catalytic	  subunit	  expression	  in	  cells	  infected	  with	  AdV.GFP-­‐B56δ-­‐WT	  was	  almost	  identical	  to	  the	  relative	  increase	  in	  B56δ	  expression	  (~11	  fold).	  These	  results	  suggest	  therefore	  that	  the	  increase	  in	  the	  expression	  of	  PP2A	  catalytic	  subunits	  is	  a	  consequence	  of	  the	  increased	  expression	  of	  B56δ	  regulatory	  subunits.	  	  








expression	   of	   heterologous	   B56δ	   increased	   with	   increasing	   dose	   of	   adenovirus,	   the	  expression	   of	   endogenous	   B56δ	   was	   similar	   in	   all	   samples,	   including	   uninfected	   cells.	  Furthermore,	   the	   expression	   profile	   suggested	   that	   a	   comparable	   abundance	   of	  heterologous	  and	  endogenous	  B56δ	  would	  be	  achieved	  with	  a	  MOI	  of	  20-­‐50.	  As	  shown	  in	  Figure	  5.9,	  the	  expression	  of	  PP2A	  catalytic	  subunits	  was	  again	  increased	  with	  increasing	  dose	  of	  adenovirus.	  	  
Further	   studies	  were	  performed	   to	   confirm	   the	  dose	  of	  AdV.GFP-­‐B56δ-­‐SA	   that	  produces	  expression	   of	   GFP-­‐B56δ-­‐SA	   at	   an	   abundance	   comparable	   to	   that	   of	   GFP-­‐B56δ-­‐WT,	  achieved	  by	   infection	  of	  myocytes	  with	  AdV.GFP-­‐B56δ-­‐WT	  at	  MOI	  30.	  The	  expression	  of	  heterologous	   proteins	   was	   determined	   by	   using	   both	   the	   B56δ	   antibody	   and	   the	   GFP	  antibody.	  As	  shown	  in	  Figure	  5.10	  (panels	  A	  and	  B),	   immunoblot	  analysis	  of	  the	  samples	  with	   either	   antibody	   revealed	   that	   comparable	   expression	   of	   each	   heterologous	   protein	  could	   be	   achieved	   by	   infecting	   myocytes	   with	   either	   adenoviral	   vector	   at	   MOI	   30.	  Furthermore,	   under	   these	   conditions	   the	   expression	   of	   catalytic	   subunits	   was	   also	  comparable	  (Figure	  5.10,	  panel	  C).	  	  	  	  	  
5.4.3 ISO-­‐induced	  phosphorylation	  of	  heterologously	  expressed	  B56δ	  at	  S573	  To	  determine	  whether	  heterologously	  expressed	  WT	  B56δ	   is	  phosphorylated	  at	   S573	   in	  response	   to	   β-­‐adrenergic	   stimulation	   and	   confirm	   that	   heterologously	   expressed	   S573A	  B56δ	   is	   not	   phosphorylated	   at	   this	   site,	   ARVM	   with	   heterologous	   expression	   of	   B56δ	  proteins	  were	  subjected	  to	  stimulation	  with	  ISO.	  Expression	  of	  B56δ	  and	  phosphorylation	  at	   S573	   were	   determined	   by	   immunoblot	   analysis	   with	   the	   B56δ	   and	   pS573	   B56δ	  antibody,	  respectively.	  As	  shown	  in	  Figure	  5.11,	  the	  B56δ	  antibody	  detected	  heterologous	  B56δ	   in	   all	   samples.	   The	   pS573	   B56δ	   antibody,	   however,	   detected	   ISO-­‐induced	  phosphorylation	   of	   S573	   only	   in	   endogenous	   and	   heterologous	   WT	   B56δ.	   Thus,	  heterologously	   expressed	   GFP-­‐B56δ-­‐WT	   is	   phosphorylated	   at	   S573	   in	   response	   to	  stimulation	  with	  ISO.	  	  




































Figure	   5.4	   DNA	   electrophoresis	   to	   confirm	   recombination	   between	   pShuttle-­‐CMV-­‐



















Figure	  5.6	  PP2A	   subunit	   expression	  profile	   in	  ARVM	   infected	  with	  AdV.GFP-­‐B56δ-­‐









Figure	  5.7	  Effect	  of	  heterologous	  expression	  of	  WT	  B56δ	  on	  PP2A	  catalytic	  subunit	  


















Figure	   5.9	   Effect	   of	   heterologous	   expression	   of	   S573A	   B56δ	   on	   the	   expression	   of	  



































5.5 Discussion	  To	  study	   the	  role	  of	  B56δ	  phosphorylation	  at	  S573	   in	  β-­‐adrenergic	   regulation	  of	  cardiac	  PP2A	   activity,	   protein	   phosphorylation	   and	   function,	   adenoviral	   vectors	   encoding	   GFP-­‐tagged	  human	  B56δ	  in	  WT	  or	  non-­‐phosphorylatable	  (S573A)	  form	  were	  constructed.	  The	  objective	   of	   the	   studies	   presented	   in	   this	   chapter	   was	   to	   characterize	   the	   use	   of	   these	  adenoviral	  vectors	  in	  ARVM.	  	  	  
The	  first	  studies	  were	  performed	  with	  AdV.GFP-­‐B56δ-­‐WT.	  On	  a	   fluorescence	  microscope	  GFP	  was	  not	  detected	  at	  18	  h	  post-­‐infection.	  Immunoblot	  analysis	  of	  infected	  cells	  with	  the	  B56δ	   antibody,	   however,	   revealed	   that	   at	   this	   time	   point	   heterologous	   B56δ	   was	  expressed.	   Furthermore,	   the	   results	   showed	   that	   expression	   at	   an	   abundance	   similar	   to	  that	  of	  endogenous	  B56δ	  was	  achieved	  by	  infection	  with	  a	  relatively	  small	  dose	  (MOI	  30)	  of	   the	  adenovirus	   (Figure	  5.5).	  The	  disparity	   in	  detection	  of	   the	  heterologous	  protein	  by	  the	  two	  methods	  may	  be	  explained	  by	  the	  fact	  that	  expression	  of	  heterologous	  B56δ,	  at	  a	  level	   that	   is	  similar	   to	   the	  expression	  of	  endogenous	  B56δ,	   is	  not	  sufficient	   to	  produce	  a	  detectable	  level	  of	  GFP	  fluorescence.	  	  








The	  unchanged	  expression	  of	  PP2A	  scaffold	  subunits	  may	  at	   first	  seem	   inconsistent	  with	  the	   increased	   expression	   of	   catalytic	   subunits,	   given	   that	   these	   are	   not	   stable	   in	   the	  absence	  of	  scaffold	  subunits.	  A	  possible	  explanation	  for	  these	  results	  may	  be	  that	  in	  ARVM	  there	  is	  an	  existing	  pool	  of	  scaffold	  subunits,	  whereas	  the	  expression	  of	  catalytic	  subunits	  is	  subject	  to	  up-­‐regulation	  (transcriptional	  or	  translational)	  when	  necessary.	  	  
Interestingly,	  at	  42	  h	  post-­‐infection	  with	  AdV.GFP-­‐B56δ-­‐WT	  at	  MOI	  ≥	  30	  the	  expression	  of	  endogenous	   B56α	   was	   reduced	   (Figure	   5.6).	   Further	   studies	   would	   be	   required	   to	  establish	  the	  underlying	  mechanism(s)	  for	  this	  response.	  However,	  a	  possible	  explanation	  for	   it	   may	   be	   that	   the	   response	   is	   compensatory;	   if	   in	   ARVM	   B56α	   and	   B56δ	   have	  redundant	  roles,	  to	  accommodate	  increased	  B56δ-­‐PP2A	  (and	  phosphatase	  activity),	  B56α-­‐PP2A	   (and	  phosphatase	  activity)	   is	   reduced.	   It	   has	  been	   reported	   that	   the	  expression	  of	  B56α	  is	  reduced,	   in	  isolated	  cardiac	  cells,	   in	  response	  to	  activation	  of	  stress	  pathways.171	  An	  alternative	  explanation	  for	  the	  loss	  of	  protein	  expression	  in	  the	  present	  studies	  may	  be	  that	  the	  response	  is	  stress-­‐induced.	  Specifically,	  it	  may	  be	  caused	  by	  the	  presence	  of	  excess	  amounts	   of	   the	   adenovirus	   and/or	   the	   prolonged	   incubation	   of	   the	   cells	   with	   the	  adenovirus.	  
With	   regards	   to	   characterization	   of	   GFP-­‐B56δ-­‐SA	   expression	   in	   ARVM,	   besides	   loss	   of	  basal-­‐	  and	  ISO-­‐induced	  phosphorylation	  at	  S573,	  differences	  from	  GFP-­‐B56δ-­‐WT	  were	  not	  observed.	  The	  full-­‐length	  protein	  was	  expressed,	   indicating	  that	  B56δ	  protein	  stability	   is	  not	   dependent	   on	   its	   phosphorylation	   at	   S573.	   Furthermore,	   the	   expression	   of	   PP2A	  catalytic	   subunits	  in	   cells	   that	   expressed	   GFP-­‐B56δ-­‐SA	  was	   not	   different	   from	   cells	   that	  expressed	  GFP-­‐B56δ-­‐WT	  at	  a	   comparable	   level,	   suggesting	   that	   the	  apparent	   interaction	  between	   the	   catalytic	   and	   heterologous	   B56δ	   subunits	   is	   also	   not	   dependent	   on	   S573	  phosphorylation	  (Figures	  5.8	  and	  5.9).	  	  
















6 The	  Role	  of	  B56δ	  Phosphorylation	  at	  S573	  in	  β-­‐Adrenergic	  Regulation	  of	  Cardiac	  PP2A	  Activity	  	  6.1 Introduction	  The	  studies	  presented	   in	  Chapter	  4	  established	   that	   in	  cardiac	  cells	  endogenous	  B56δ	   is	  phosphorylated	  by	  PKA	  at	  S573	  in	  β-­‐adrenergic	  signaling.	  The	  role	  of	  the	  phosphorylation	  in	  β-­‐adrenergic	  regulation	  of	  cardiac	  PP2A	  activity,	  however,	   is	  unknown.	   In	  vitro	  and	   in	  non-­‐cardiac	   cells,	   the	   phosphorylation	   of	   B56δ	   at	   S573	   is	   necessary	   and	   sufficient	   to	  stimulate	   the	   activity	   of	   the	   associated	   catalytic	   subunit,	   increasing	   both	   the	   rate	   of	  substrate	   dephosphorylation	   and	   substrate	   affinity.114,186	   In	   these	   published	   studies	   the	  activity	   of	   B56δ-­‐PP2A	  was	   determined	   in	   vitro	   by	   measuring	   the	   radioactivity	   released	  from	  radiolabeled	  phospho-­‐proteins.	  These	  were	  either	  standard	  phospho-­‐proteins	  used	  in	   in	  vitro	   phosphatase	  assays	   (i.e.	  histone	  2B,	  histone	  1	  and	  phosphorylase	  a),186	  or	   the	  purified	   substrate	   phospho-­‐protein	   of	   B56δ-­‐PP2A	   identified	   in	   mouse	   striatum	   (i.e.	  DARPP-­‐32,	  dopamine-­‐	  and	  cAMP-­‐regulated	  neuronal	  phosphorotein).114	  	  
















6.2 Objectives	  The	  objectives	  of	  the	  studies	  described	  in	  this	  chapter	  were	  to:	  
• Determine	   the	   suitability	   of	   a	   PP2A	   immunoprecipitation	   phosphatase	   assay	   for	  assessment	  of	  PP2A	  activity	  in	  ARVM.	  








6.3 Methods	  6.3.1 ARVM	  isolation,	  culture,	  adenoviral	  gene	  transfer	  and	  stimulation	  For	   the	   experiments	   described	   in	   this	   chapter,	   ARVM	  were	   isolated	   from	   the	   hearts	   of	  adult	  male	  Wistar	  rats	  and	  cultured	  as	  described	  in	  the	  Methods	  (sections	  2.1.1	  and	  2.1.2).	  Where	   indicated,	   infection	   with	   adenoviral	   vectors	   was	   performed	   as	   described	   in	   the	  Methods	  (section	  2.1.3).	  The	  cells	  were	  exposed	  to	  vehicle	  or	  10	  nM	  ISO	  (10	  min,	  37oC)	  18	  h	  post-­‐infection.	  
6.3.2 Measurament	  of	  PP2A	  activity	  PP2A	  phosphatase	  activity	  was	  determined	  as	  described	   in	   the	  methods	  (section	  2.6).	   In	  brief,	  the	  catalytic	  subunits	  of	  PP2A	  were	  immunoprecipitated	  from	  clarified	  ARVM	  lysates	  with	   a	   mouse	   monoclonal	   subunit-­‐specific	   antibody.	   The	   immunoprecipitates	   were	  incubated	  with	  the	  substrate	  Thr	  phospho-­‐peptide	  (750	  μM,	  10	  min).	  25	  μL	  of	  the	  reaction	  end-­‐product	  was	  assayed	  with	  malachite	  green	  phosphate	  detection	  solution	  in	  wells	  of	  a	  96-­‐well	  ½	  volume	  microtiter	  plate.	  The	  absorbance	  of	   the	   sample	  was	  measured	  at	  650	  nm	  and	  the	  phosphate	  concentration	  was	  interpolated	  from	  the	  phosphate	  standard	  curve.	  Phosphatase	   activity,	   expressed	   as	   pmol	   phosphate	   released	   from	   the	   Thr	   phospho-­‐peptide	   per	   min	   (pmol	   Pi/min),	   was	   calculated	   as	   described	   in	   the	   Methods	   (section	  2.6.4.3).	  	  	  








6.4 Results	  6.4.1 Validation	  of	  PP2A	  immunoprecipitation	  phosphatase	  assay	  
 	  Malachite	  green	  phosphate	  detection	  solution	  6.4.1.1To	  validate	  the	  use	  of	  malachite	  green	  phosphate	  detection	  solution,	  phosphate	  standards	  containing	  between	  0	  and	  2000	  pmol	  phosphate	  per	  25	  μL	  were	  prepared	  and	  100	  μL	  of	  the	  solution	  was	  added	  to	  25	  μL	  of	  each	  standard.	  As	  shown	   in	  Figure	  6.1	  (panel	  A),	   the	  colour	   intensity	   increased	  with	   increasing	  phosphate	   concentration.	  As	   shown	   in	   Figure	  6.1	  (panel	  B),	  the	  absorbance	  of	  the	  standards	  at	  650	  nm	  was	  directly	  proportional	  to	  the	  phosphate	  concentration.	  Thus,	  malachite	  green	  phosphate	  detection	  solution	  can	  detect	  small	   amounts	   of	   phosphate	   and	   the	   assay	   is	   linear	   over	   a	   wide	   range	   of	   phosphate	  concentrations.	  	  








immunoprecipitate	   (IP)	   and	   post-­‐immunoprecipitation	   (post-­‐IP)	   supernatant,	   by	  immunoblot	   analysis.	   As	   shown	   in	   Figure	   6.2	   (panel	   D),	   PP2A	   catalytic	   subunits	   were	  substantially	  enriched	  in	  the	  IP.	  Together,	  these	  results	  show	  that	  immunoprecipitation	  of	  PP2A	  catalytic	  subunits	  is	  specific	  and	  efficient.	  	  



































6.5 Discussion	  The	   ultimate	   aim	   of	   the	   studies	   described	   in	   this	   chapter	   was	   to	   determine	   the	   role	   of	  B56δ	   phosphorylation	   at	   S573	   in	   β-­‐adrenergic	   regulation	   of	   cardiac	   PP2A	   activity.	   To	  specifically	   determine	   the	   activity	   of	   PP2A,	   the	   catalytic	   subunits	   were	   isolated	   from	  soluble	   ARVM	   lysates	   by	   immunoprecipitation	   and	   their	   activity	   was	   determined	   by	  measuring	   the	   amount	   of	   inorganic	   phosphate	   released	   from	   a	   substrate	   Thr	   phospho-­‐peptide.	  	  
The	  sensitivity	  and	  specificity	  of	  the	  PP2A	  immunoprecipitation	  phosphatase	  assay	  were	  determined	   in	   validation	   studies.	   The	   results	   showed	   that	   small	   (picomolar)	  concentrations	   of	   inorganic	   phosphates	   can	   be	   detected	   in	   this	   assay	   and	   that	   the	  relationship	   between	   the	   absorbance	   and	   phosphate	   concentration	   is	   linear	   over	   a	  considerably	   wide	   range	   of	   concentrations.	   Furthermore,	   the	   immunoprecipitation	   of	  PP2A	   catalytic	   subunits	   is	   specific	   and	   efficient	   (Figures	   6.1	   and	   6.2).	   The	   PP2A	  immunoprecipitation	   phosphatase	   assay	   was	   thus	   considered	   an	   appropriate	   assay	   to	  determine	  the	  role	  of	  B56δ	  phosphorylation	  at	  S573	  in	  β-­‐adrenergic	  regulation	  of	  cardiac	  PP2A	   activity.	   To	   this	   purpose,	   human	  WT	   or	   non-­‐phosphorylatable	   (S573A)	   B56δ	  was	  heterologously	   expressed	   in	   ARVM	   by	   adenoviral	   gene	   transfer	   and	   PP2A	   activity	   was	  determined	  in	  the	  absence	  and	  presence	  of	  ISO	  stimulation.	  	  








B56δ	  and	  those	  expressing	  S573A	  B56δ,	  particularly	  following	  β-­‐adrenergic	  stimulation,	  is	  surprising.	  	  The	  assay	  used	  detects	  total	  PP2A	  activity	  and	  not	  the	  specific	  activity	  of	  PP2A	  holoenzymes	   targeted	   by	   heterologous	   B56δ	   subunits.	   Thus,	   if	   the	   latter	   represent	   a	  relatively	  small	  proportion	  of	  the	  total	  cellular	  PP2A	  holoenzyme	  content,	  then	  the	  results	  become	   less	   surprising.	   In	   this	   context,	   it	   is	   possible	   that	   different	   PP2A	   holoenzymes	  respond	  differentially	  to	  β-­‐adrenergic	  stimulation,	  such	  that	  measuring	  total	  PP2A	  activity	  would	  mask	   the	   changes	   in	   the	   activity	   of	   specific	   holoenzymes.	   Furthermore,	   it	   is	   also	  possible	  that	  expression	  of	  non-­‐phosphorylatable	  B56δ	  was	  not	  sufficient	  to	  overcome	  the	  effect	  of	  the	  endogenous	  protein.	  	  








7 The	  Role	  of	  B56δ	  Phosphorylation	  at	  S573	  in	  β-­‐Adrenergic	  Regulation	  of	  Cardiac	  Protein	  Phosphorylation	  7.1 Introduction	  As	   described	   in	   previous	   chapters	   of	   this	   thesis,	   thus	   far	   the	   functional	   role	   of	   PKA-­‐mediated	  B56δ	  phosphorylation	  at	  S573	  has	  been	  explored	  only	  in	  mouse	  striatal	  neurons	  and	  in	  rat	  preovulatory	  ovarian	  granulosa	  cells.	  	  
In	  striatal	  neurons	  the	  phosphorylation	  of	   the	  PP2A	  regulatory	  subunit	  and	  activation	  of	  PP2A	   represents	   a	   positive	   feedback	   mechanism.114	   Accordingly,	   by	   stimulating	   the	  dephosphorylation	   of	   the	   PP1	   regulatory	   protein	   DARPP-­‐32	   at	   T75,	   PKA-­‐mediated	  phosphorylation	  of	  T34	  is	  facilitated	  and	  DARPP-­‐32	  is	  converted	  into	  a	  potent	  inhibitor	  of	  PP1.114	  Consequently,	  PP1	  activity	   is	   inhibited	  and	  PKA	  signaling	   is	   amplified.	   In	   further	  studies	   the	   B56δ	   S573	   phosphorylation	   correlated	   with	   reduced	   phosphorylation	   of	  DARPP-­‐32	   at	   S97.208	   This	   was	   associated	   with	   nuclear	   retention	   of	   DARPP-­‐32,	   reduced	  activity	  of	  nuclear	  PP1	  and	  increased	  phosphorylation	  of	  histones.	  	  
In	   rat	   preovulatory	   ovarian	   granulosa	   cells,	   PKA-­‐mediated	   phosphorylation	   of	   B56δ	   at	  S573	   induces	   dephosphorylation	   of	  MAP	  2D,	  which	   is	   phosphorylated	   at	   T256/T259	  by	  glycogen	   synthase	   kinase	   3β	   (GSK3β)	   under	   basal	   conditions.187	   Τhe	   dephosphorylation	  occurs	   downstream	   of	   LH	   receptor	   and	   is	   the	   net	   effect	   of	   simultaneous	   PKA-­‐mediated	  inactivation	  of	  GSK3β	  and	  activation	  of	  B56δ-­‐PP2A.	  
















7.2 Objectives	  The	  objectives	  of	  the	  studies	  described	  in	  this	  chapter	  were	  to:	  
• Determine	   the	   phosphorylation	   of	   generic	   PKA	   substrates	   in	   ARVM	   with	  heterologous	   expression	   of	   GFP,	   GFP-­‐B56δ-­‐WT	   or	   GFP-­‐B56δ-­‐SA,	   in	   the	   absence	  and	  presence	  of	  β-­‐adrenergic	  stimulation	  by	  ISO.	  








7.3 Methods	  7.3.1 ARVM	  isolation,	  culture,	  adenoviral	  gene	  transfer	  and	  stimulation	  For	   the	   experiments	   described	   in	   this	   chapter,	   ARVM	  were	   isolated	   from	   the	   hearts	   of	  adult	  male	  Wistar	  rats	  and	  cultured	  as	  described	  in	  the	  Methods	  (sections	  2.1.1	  and	  2.1.2).	  Infection	   with	   adenoviral	   vectors	   was	   performed	   as	   described	   in	   the	   Methods	   (section	  2.1.3).	  The	  cells	  were	  exposed	  to	  vehicle	  or	  ISO	  (0.1-­‐10	  nM)	  for	  10	  min	  (37oC),	  18	  h	  post-­‐infection.	   For	   immunoblot	   analysis	   of	   protein	   expression	   and	   phosphorylation,	   the	   cells	  were	   harvested	   in	   cell	   lysis	   buffer	   (200	   μL	   per	   well).	   The	   protein	   concentration	   was	  determined	  as	  described	  in	  the	  Methods	  (section	  2.5.1).	  	  








7.4 Results	  The	  ultimate	  objective	  of	  the	  studies	  described	  in	  this	  chapter	  was	  to	  determine	  the	  role	  of	  B56δ	   phosphorylation	   at	   S573	   in	   β-­‐adrenergic	   regulation	   of	   cardiac	   protein	  phosphorylation.	  However,	  due	  to	  difficulties	  encountered	  in	  constructing	  AdV.GFP-­‐B56δ-­‐SA,	  the	  effect	  of	  increased	  B56δ	  expression	  was	  explored	  first.	  	  
7.4.1 Effect	  of	  increased	  B56δ	  expression	  on	  β-­‐adrenergic	  regulation	  of	  cardiac	  protein	  phosphorylation	  
 Optimizing	  the	  dose	  of	  AdV.GFP	  7.4.1.1To	   determine	   the	   dose	   of	   AdV.GFP	   that	   expresses	   GFP	   at	   a	   level	   comparable	   to	   that	  achieved	  by	  AdV.GFP-­‐B56δ-­‐WT	  at	  MOI	  30,	  ARVM	  were	  infected	  with	  AdV.GFP	  (MOI	  5-­‐30)	  or	  AdV.GFP-­‐B56δ-­‐WT	   (MOI	   30).	   The	   expression	   of	   GFP	  was	   determined	  by	   immunoblot	  analysis	   18	   h	   post-­‐infection.	   As	   shown	   in	   Figure	   7.1,	   the	   expression	   of	   GFP	   (~30-­‐kDa)	  increased	  with	  increasing	  dose	  of	  AdV.GFP	  and	  at	  MOI	  5	  its	  expression	  was	  comparable	  to	  the	   expression	   of	   GFP-­‐B56δ-­‐WT	   (~100-­‐kDa).	   Due	   to	   differences	   in	   molecular	   weights,	  under	  the	  same	  electrophoretic	  transfer	  conditions	  the	  transfer	  of	  GFP	  was	  probably	  more	  efficient	   than	   the	   transfer	   of	   GFP-­‐B56δ-­‐WT.	   Thus,	   to	   account	   for	   a	   relative	  underestimation	  of	  GFP-­‐B56δ-­‐WT	  expression,	  in	  subsequent	  studies	  AdV.GFP	  was	  used	  at	  MOI	   10.	   The	   GFP	   antibody	   detected	   an	   additional	   protein	   with	   an	   apparent	   molecular	  weight	  of	  ~40	  kDa.	  This	  protein	  was	  also	  detected	  in	  uninfected	  cells	  and	  thus,	  the	  signal	  was	  non-­‐specific.	  	  	  








increasing	   concentrations	   of	   ISO	   (0.1-­‐10	   nM)	   or	   vehicle	   and	   samples	   of	   total	   cellular	  lysates	   were	   resolved	   by	   electrophoresis	   in	   a	   15%	   acrylamide	   gel.	   To	   determine	   the	  phosphorylation	   status	   of	   generic	   PKA	   substrates,	   immunoblot	   analysis	   was	   performed	  with	   a	   rabbit	   monoclonal	   antibody	   that	   recognizes	   the	   RRXS*/T*	   motif	   (where	   R	   =	  arginine;	   X	   =	   any	   amino	   acid;	   S*/T*	   =	   phosphorylated	   Ser	   or	   Thr).	   By	   recognizing	  phosphorylated	   Ser/Thr	   residues	   in	   the	   PKA	   consensus	   phosphorylation	   motif,	   the	  phospho-­‐PKA	   substrate	   antibody	   can	   detect	  multiple	   PKA	   substrates	   simultaneously.	   As	  shown	   in	   Figure	   7.2	   (panel	   A),	   the	   antibody	   detected	   several	   proteins	   whose	  phosphorylation	   was	   increased	   by	   ISO	   in	   a	   dose-­‐dependent	   manner.	   Given	   that	   the	  antibody	   does	   not	   recognize	   the	   non-­‐phosphorylated	   motif	   (as	   stated	   by	   Cell	   Signaling	  Technology	  at	  the	  time	  of	  these	  studies),	  it	  is	  implicit	  that	  in	  unstimulated	  cells	  the	  basal	  phosphorylation	   of	   PKA	   substrates	   was	   detected.	   An	   interesting	   observation	   in	   this	  experiment	   was	   the	   increased	   phosphorylation	   of	   some	   PKA	   substrates	   in	   ARVM	   that	  expressed	  GFP-­‐B56δ-­‐WT.	  This	  was	  most	  pronounced	  for	  proteins	  with	  a	  molecular	  weight	  ≥150-­‐kDa,	   following	   stimulation	   by	   ISO	   at	   1	   nM	   and	   10	   nM.	   To	   determine	   the	   relative	  abundance	  of	  heterologous	  and	  endogenous	  B56δ	  proteins,	  the	  samples	  were	  subjected	  to	  immunoblot	   analysis	   with	   the	   B56δ	   antibody.	   As	   shown	   by	   Figure	   7.2	   (panel	   B),	   the	  expression	   of	   the	   two	   proteins	   was	   comparable.	   Together,	   these	   first	   results	   suggested	  that	   ISO-­‐induced	  phosphorylation	   of	   some	  PKA	   substrates	  was	   increased	   in	   cells	  with	   a	  moderate	  expression	  of	  heterologous	  WT	  B56δ.	  	  	  	  
7.4.2 The	  role	  of	  B56δ	  phosphorylation	  at	  S573	  in	  β-­‐adrenergic	  regulation	  of	  cardiac	  protein	  phosphorylation	  








phospho-­‐PKA	   substrate	   antibody.	   On	   this	   occasion,	   the	   phosphorylation	   status	   of	   larger	  proteins	   was	   less	   clear	   but	   the	   phosphorylation	   status	   of	   smaller	   proteins	   was	   readily	  detected	   (Figure	   7.3,	   panel	   A).	   As	   expected,	   the	   phosphorylation	   of	   PKA	   substrates	  was	  increased	  by	   ISO	   in	  a	  dose-­‐dependent	  manner,	  with	  strong	  signals	  observed	  at	  ~30-­‐kDa	  and	   <15-­‐kDa.	   Basal	   phosphorylation	   was	   revealed	   only	   for	   proteins	   with	   a	   molecular	  weight	   <15-­‐kDa.	   A	   striking	   result	   was	   the	   reduced	   phosphorylation	   of	   protein(s)	  migrating	   at	  ~30-­‐kDa	   in	   cells	   expressing	  GFP-­‐B56δ-­‐SA	   following	   stimulation	  with	   1	   nM	  ISO.	  	  
To	  gain	  better	  insight	  on	  the	  phosphorylation	  status	  of	  larger	  proteins	  the	  lysates	  of	  cells	  harvested	  in	  a	  subsequent	  experiment	  were	  resolved	  in	  a	  7.5%	  acrylamide	  gel.	  As	  shown	  in	   Figure	   7.3	   (panel	   B),	   the	   ISO-­‐induced	   phosphorylation	   of	   putative	   PKA	   substrates	  migrating	   at	   150-­‐kDa	   and	   ~60-­‐kDa	   was	   revealed.	   Interestingly,	   whilst	   the	   increase	   in	  phosphorylation	   of	   150-­‐kDa	   proteins	   was	   dose-­‐dependent,	   the	   phosphorylation	   of	  proteins	  migrating	  at	  ~60-­‐kDa	  was	  similar	   following	  stimulation	  with	  either	  1	  nM	  or	  10	  nM	   ISO.	   Differential	   phosphorylation	   of	   proteins	   (in	   cells	   that	   expressed	   a	   different	  heterologous	   protein)	   was	   observed	   in	   response	   to	   stimulation	   by	   ISO	   at	   1	   nM.	  Accordingly,	  when	  compared	   to	   cells	   that	   expressed	  GFP-­‐B56δ-­‐WT,	   the	  phosphorylation	  of	   150-­‐kDa	   and	   ~60-­‐kDa	   proteins	   was	   reduced	   in	   cells	   that	   expressed	   GFP-­‐B56δ-­‐SA.	  Furthermore,	  when	  compared	  to	  cells	  that	  expressed	  GFP,	  the	  phosphorylation	  of	  150-­‐kDa	  proteins	   was	   increased	   in	   cells	   that	   expressed	   GFP-­‐B56δ-­‐WT.	   Taken	   together,	   these	  studies	   showed	   that	   the	   ISO-­‐induced	   phosphorylation	   of	   some	   PKA	   substrates	   was	  reduced	  in	  cells	  that	  expressed	  non-­‐phosphorylatable	  B56δ.	  Furthermore,	  it	  appeared	  that	  the	   phosphorylation	   of	   some	   PKA	   substrates	   was	   amplified	   by	   the	   heterologous	  expression	  of	  WT	  B56δ.	  	  


























Figure	   7.2	  The	   role	   of	   B56δ	   expression	   in	   β-­‐adrenergic	   regulation	   of	   generic	   PKA	  

















Figure	  7.3	  The	  role	  of	  B56δ	  phosphorylation	  at	  S573	   in	  β-­‐adrenergic	  regulation	  of	  


















Figure	  7.5	  The	  role	  of	  B56δ	  phosphorylation	  at	  S573	   in	  β-­‐adrenergic	  regulation	  of	  
specific	  PKA	  substrate	  phosphorylation	  	  ARVM	  expressing	  GFP,	  GFP-­‐B56δ-­‐WT	  or	  GFP-­‐B56δ-­‐SA	  were	  exposed	  to	  vehicle	  (veh)	  or	  ISO	  (1	  nM	  or	  10	  nM)	  for	  10	  min.	  Figures	  show	  the	  phosphorylation	  of	  A.	  PLB	  at	  S16;	  B.	  cTnI	  at	  S23/24	  and	  C.	  cMyBP-­‐C	   at	   S282.	   Bar	   charts	   show	   the	   signals	   detected	   in	   the	   immunoblots	   for	   protein	  phosphorylation	   in	  response	  to	  stimulation	  with	  1	  nM	  ISO.	  The	  signal	  generated	  by	  the	  phospho-­‐specific	   antibody	   was	   normalized	   to	   the	   signal	   generated	   by	   the	   antibody	   detecting	   the	   total	  protein.	  	  	  	  
	  








7.5 Discussion	  The	  primary	  objective	  of	   the	  studies	  described	   in	   this	  chapter	  was	  to	  explore	  the	  role	  of	  B56δ	   phosphorylation	   at	   S573	   in	   β-­‐adrenergic	   regulation	   of	   cardiac	   protein	  phosphorylation.	  The	  studies	  were	  performed	  in	  ARVM	  expressing	  heterologous	  B56δ	  in	  WT	  or	  non-­‐phosphorylatable	  (S573A)	  form.	  In	  these	  particular	  studies	  the	  impact	  of	  S573	  phosphorylation	   was	   determined	   in	   the	   context	   of	   β-­‐adrenergic	   regulation	   of	   PKA	  substrate	  phosphorylation.	  	  
Whilst	  the	  construction	  of	  AdV.GFP-­‐B56δ-­‐SA	  was	  being	  completed,	  the	  effect	  of	  increased	  B56δ	   expression,	   which	   has	   been	   reported	   in	   both	   ischemic	   and	   non-­‐ischemic	   canine	  models	   of	   heart	   disease,183	   was	   explored.	   In	   these	   first	   studies	   GFP	   or	   GFP-­‐B56δ-­‐WT	  proteins	  were	  expressed	  at	  a	  comparable	  level	  in	  ARVM	  (Figure	  7.1).	  The	  decision	  to	  study	  the	  phosphorylation	  of	  PKA	  substrates	  was	  guided	  by	   the	  evidence,	   in	  non-­‐cardiac	   cells,	  that	  PKA-­‐mediated	  phosphorylation	  of	  B56δ	  at	  S573	  impacts	  on	  PKA	  signaling.114,177	  	  
The	  phosphorylation	  of	  generic	  PKA	  substrates	  was	  determined	  by	   immunoblot	  analysis	  with	  a	  phospho-­‐motif-­‐specific	  antibody.	  This	  antibody	  recognizes	  phosphorylated	  Ser	  and	  Thr	   residues	   in	   the	   PKA	   consensus	   phosphorylation	  motif,	  with	   arginine	   at	   positions	   -­‐2	  and	   -­‐3	   relative	   to	   the	   site	   of	   phosphorylation.209	   By	   using	   this	   antibody,	   the	  phosphorylation	   status	   of	  multiple	   PKA	   substrate	   proteins	  was	   revealed	   simultaneously	  (Figures	  7.2	  and	  7.3).	  Considering	   the	  plethora	  of	  proteins	  phosphorylated	  by	  PKA	   in	  β-­‐adrenergic	  signaling,210	  it	  is	  clear	  that	  in	  the	  present	  studies	  only	  a	  few	  phospho-­‐proteins,	  most	   likely	   the	   abundant	   phospho-­‐proteins,	   were	   detected.	   It	   is	   of	   course	   also	   possible	  that	   multiple	   substrates	   of	   PKA	   with	   an	   identical	   or	   similar	   molecular	   weight	   were	  detected	   in	   clusters.	   It	   is	   also	   important	   to	   be	   aware	   of	   the	   fact	   that	   several	   targets,	  including	   cTnI	   and	   cMyBP-­‐C,	   are	   phosphorylated	   by	   PKA	   at	   multiple	   sites	   and	   the	  phospho-­‐PKA	  substrate	  antibody	  may	  detect	  only	  some	  of	  these.	  	  








when	   compared	   to	   ARVM	   expressing	   GFP-­‐B56δ-­‐WT	   at	   a	   comparable	   abundance,	   the	  phosphorylation	   of	   PKA	   substrates	   was	   reduced	   in	   cells	   expressing	   GFP-­‐B56δ-­‐S573A	  (Figure	   7.3	   and	   7.4).	   In	   the	   light	   of	   evidence	   that	   the	   phosphorylation	   of	   B56δ	   at	   S573	  increases	   the	   phosphatase	   activity	   of	   the	   associated	   catalytic	   subunit,114	   these	   findings	  seemed	  paradoxical.	  If	  the	  phosphorylation	  of	  B56δ	  induces	  the	  dephosphorylation	  of	  PKA	  substrates,	   the	   phosphorylation	   of	   these	   substrates	   would	   be	   increased,	   rather	   than	  decreased,	   in	   cells	   expressing	  GFP-­‐B56δ-­‐SA.	  Furthermore,	   in	   cells	   expressing	  GFP-­‐B56δ-­‐WT	   the	  phosphorylation	  of	   the	   substrates	  would	  be	   reduced,	   particularly	   in	   view	  of	   the	  parallel	   increase	   in	   the	   expression	   of	   PP2A	   catalytic	   subunits	   (Figure	   7.4).	   Thus,	   an	  alternative	  and	  reasonable	  explanation	  is	  that	  in	  cardiac	  myocytes	  the	  phosphorylation	  of	  B56δ	   at	   S573	   mediates	   positive	   feedback,	   enhancing	   the	   phosphorylation	   of	   PKA	  substrates.	  It	  is	  worth	  noting	  that	  on	  most	  occasions,	  the	  discussed	  effects	  were	  observed	  in	   the	   presence	   of	   1	   nM	   but	   not	   10	   nM	   ISO.	   It	   is	   therefore	   possible	   that	   the	   positive	  feedback	   mechanism	   becomes	   redundant	   in	   the	   presence	   of	   supra-­‐maximal	   β-­‐AR	  stimulation.	  	  	  	  








suggest	   that	   in	   cardiac	   myocytes	   B56δ	   phosphorylation	   at	   S573	   may	   mediate	   positive	  feedback,	  amplifying	  the	  phosphorylation	  of	  at	  least	  some	  PKA	  substrate	  proteins.	  	  
The	  findings,	  although	  surprising	  at	  first,	  are	  consistent	  with	  some	  of	  the	  proposed	  roles	  of	  B56δ	  S573	  phosphorylation	   in	  non-­‐cardiac	  cells.	  For	  example,	   in	  mouse	  striatal	  neurons	  the	  phosphorylation	  of	  B56δ	  (which	  activates	  the	  pertinent	  PP2A	  holoenzyme)	  facilitates	  the	  conversion	  of	  DARPP-­‐32	   into	  a	  potent	   inhibitor	  of	  PP1.114	  Consequently,	  by	  reducing	  PP1	   phosphatase	   activity,	   substrate	   phosphorylation	   is	   enhanced.	   The	   second	   example	  comes	  from	  studies	  in	  HEK293	  cells.	  These	  studies,	  albeit	  performed	  with	  heterologously	  expressed	   proteins,	   suggest	   that	   PKA-­‐mediated	   B56δ	   phosphorylation	   stimulates	  dephosphorylation	  of	  PDE4D3.177	  This	  reduces	  the	  degradation	  of	  cAMP,	  potentiating	  PKA	  activation	  and	  thereby	  substrate	  phosphorylation.177	  








8 Summary	  and	  Perspectives	  	  
B-­‐type	   subunits	   determine	   the	   subcellular	   targeting	   of	   PP2A	   holoenzymes	   and	   regulate	  the	   substrate	   selectivity	   and	  activity	  of	   the	   catalytic	   subunit.	  Although	  cardiac	  PP2A	  has	  been	  implicated	  in	  physiological	  and	  pathophysiological	  events,	  the	  roles	  of	  the	  individual	  B-­‐type	   subunits	   and	   the	   mechanisms	   of	   their	   regulation	   are	   not	   well	   defined.	   Previous	  work	   in	   our	   laboratory	   showed	   that	   the	   regulatory	   B56α	   subunit	   is	   depleted	   from	   the	  myofilaments	   of	   ARVM	   in	   response	   to	   ISO	   stimulation.166	   This	   encouraged	   further	  investigation	   of	   the	   role	   of	   B56	   subunits	   in	   β-­‐adrenergic	   regulation	   of	   cardiac	   PP2A,	  forming	  the	  basis	  of	  the	  studies	  in	  this	  thesis.	  	  
The	   studies	   in	   chapter	   3	   assessed	   the	   expression	   of	   B56α,	   -­‐γ	   and	   -­‐δ	   at	   protein	   level	   in	  ARVM	  and	  determined	  their	  subcellular	  distribution	  by	  fractionation.	  The	  data	  confirmed	  the	   ISO-­‐induced	   translocation	   of	   B56α	   and	   showed	   that	   the	   response	   is	   unique	   to	   this	  isoform.	  Furthermore,	  a	  parallel	   ISO-­‐induced	  translocation	  of	  PP2A	  scaffold	  and	  catalytic	  subunits	  was	  revealed.	  Expanding	  upon	  previous	  findings,	  these	  results	  suggested	  that	  ISO	  induces	  the	  translocation	  of	  selected	  myofilament-­‐residing	  PP2A	  holoenzymes,	  rather	  than	  of	  individual	  regulatory	  subunits.	  	  








The	  majority	  of	  the	  studies	  reported	  in	  this	  thesis	  focus	  on	  the	  phosphorylation	  of	  B56δ	  at	  S573	   by	   PKA.	   In	   vitro,	   such	   phosphorylation	   modulates	   the	   substrate	   specificity	   of	   the	  holoenzyme.186	   Furthermore,	   in	   transfected	   HEK293	   cells	   and	   in	   neurons,	   this	  phosphorylation	   is	   necessary	   and	   sufficient	   to	   stimulate	   the	   activity	   of	   the	   associated	  PP2A	   catalytic	   subunit.114	   This	   raises	   the	   possibility	   that	   in	   ARVM	   PKA-­‐mediated	  phosphorylation	   of	   B56δ	   at	   S573	   may	   facilitate	   the	   dephosphorylation	   of	   B56δ-­‐PP2A	  substrate	  proteins.	  Given	   the	   rapid	  onset	   of	  phosphorylation,	   it	   is	   conceivable	   that	   in	  β-­‐adrenergic	   signaling	   distinct	   proteins	   are	   phosphorylated	   and	   dephosphorylated	  simultaneously.	  This	  could	  occur	  to	  either	  attenuate	  the	  effects	  of	  protein	  kinases	  that	  are	  activated	   downstream	   of	   β-­‐ARs	   (PKA	   and	   CaMKII),	   or	   induce	   other	   dephosphorylation-­‐dependent	  responses.	  	  	  	  	  	  
Immunofluorescence	   studies	  of	  B56δ	   showed	   that	   it	   is	  present	   throughout	   the	  myocyte,	  including	  the	  nucleus	  (chapter	  4).	  Given	  the	  targeting	  function	  of	  the	  regulatory	  subunits,	  the	  absence	  of	  a	  more	  discrete	  localization	  was	  surprising.	  However,	  there	  is	  evidence	  in	  other	   cell	   types	   that	   B56δ-­‐PP2A	   regulates	   the	   phosphorylation	   of	   both	   nuclear	   and	  cytosolic	  proteins;	  in	  trophoblast	  stem	  cells,	  it	  regulates	  HAND	  transcription	  factors	  in	  the	  nucleus.213	   In	   neurons	   and	   pre-­‐ovulatory	   follicles,	   it	   regulates	  MAPs	   in	   the	   cytosol.120,214	  Therefore,	  it	  is	  possible	  that	  in	  myocytes	  the	  holoenzyme	  regulates	  the	  phosphorylation	  of	  specific	  substrates	  in	  multiple	  subcellular	  compartments.	  	  
The	  fractionation	  studies	  in	  chapter	  3,	  and	  the	  immunofluorescence	  studies	  in	  chapter	  4,	  showed	   that	   the	   subcellular	   localization	   of	   B56δ	   is	   not	   altered	   by	   ISO	   stimulation.	   It	   is	  therefore	   conceivable	   that	   this	   subunit	   targets	   the	   holoenzyme	   to	   its	   substrates	  constitutively,	  and	  that	  its	  phosphorylation	  by	  PKA	  induces	  their	  dephosphorylation.	  Once	  again,	  this	  highlights	  the	  differential	  regulation	  of	  B56	  holoenzymes.	  In	  this	  context,	  it	  may	  be	  hypothesized	  that	  the	  translocation	  of	  the	  B56α	  holoenzyme	  from	  the	  myofilaments	  of	  ARVM	  would	  lead	  to	  the	  dephosphorylation	  of	  B56α-­‐PP2A	  substrates	  elsewhere.	  	  	  	  	  	  	  








increase	  in	  the	  expression	  of	  PP2A	  catalytic	  subunits,	  suggesting	  that	  either	  heterologous	  subunit	  was	   incorporated	   into	  holoenzymes	  (chapter	  5).	   In	   future	  studies,	   this	  would	  be	  confirmed	  by	  immunoprecipitating	  the	  heterologous	  subunits	  via	  the	  GFP-­‐tag	  and	  probing	  the	  immunoprecipitates	  for	  the	  presence	  of	  PP2A	  catalytic	  and	  scaffold	  subunits.	  Related	  to	   this,	   the	   activity	   of	   the	   immunoprecipitated	   holoenzymes	   would	   be	   determined	   by	  performing	   the	   malachite	   green	   assay.	   Given	   the	   evidence	   that	   B56δ	   S573	  phosphorylation	  stimulates	  the	  activity	  of	  the	  associated	  catalytic	  subunit,114	  it	  is	  expected	  that	   ISO	   stimulation	   would	   increase	   the	   activity	   of	   holoenzymes	   containing	   the	   WT	  subunit	  but	  not	  the	  S573A	  mutant.	  	  
Given	  that	  a	  large	  proportion	  of	  cardiac	  responses	  to	  β-­‐adrenergic	  stimuli	  result	  from	  the	  phosphorylation	  of	  proteins	  by	  PKA	  and	  that	  PP2A	  has	  been	  implicated	  in	  the	  regulation	  of	   PKA	   substrate	   phosphorylation	   in	   β-­‐adrenergic	   signaling,127	   the	   hypothesis	   that	   the	  phosphorylation	  of	  B56δ	  at	  S573	  impacts	  on	  the	  phosphorylation	  of	  PKA	  substrates	  was	  explored	  (Chapter	  7).	  The	  phosphorylation	  of	  generic	  PKA	  substrates	  was	  determined	  by	  immunoblot	   analysis	   with	   a	   phospho-­‐PKA	   substrate	   antibody	   in	   ARVM	   expressing	  heterologous	  WT	  or	  S573A	  B56δ.	  Although	  their	  identity	  is	  unknown,	  the	  phosphorylation	  of	  some	  proteins	  appeared	  increased	  in	  cells	  expressing	  WT	  B56δ	  and	  decreased	  in	  cells	  expressing	  S573A	  B56δ.	  This	  was	  most	  apparent	   following	  stimulation	  with	  a	   lower	   ISO	  concentration,	   suggesting	   that	   the	   phosphorylation	   of	   B56δ	   at	   S573	   may	   amplify	   PKA	  signaling	  in	  response	  to	  sub-­‐maximal	  β-­‐AR	  stimulation.	  	  








Assuming	   that	   the	   expression	   of	   PKA	   is	   not	   altered	   in	   the	   experimental	   system,	   an	  alternative	  explanation	  for	  the	  findings	  can	  be	  proposed.	  In	  neurons,	  the	  phosphorylation	  of	   B56δ	   at	   S573	   by	   PKA	   amplifies	   cAMP	   and	   PKA	   signaling	   by	   reducing	   PP1	   activity.114	  This	   effect	   is	  mediated	   by	   B56δ-­‐PP2A-­‐mediated	   dephosphorylation	   of	   the	   PP1	   inhibitor	  DARPP-­‐32,	  which	  increases	  its	  PP1-­‐inhibitory	  activity.114	  This	   is	   illustrated	  schematically	  in	   Figure	   8.1	   (panel	   A).	   Given	   that	   the	   expression	   of	   DARPP-­‐32	   is	   negligible	   in	   non-­‐neuronal	  cells,215,216	  DARPP-­‐32	  is	  unlikely	  to	  regulate	  PP1	  in	  myocytes.	  Nevertheless,	   the	  structural	   and	   functional	   homologue	   of	   DARPP-­‐32	   that	   regulates	   PP1	   activity	   in	  cardiomyocytes	   is	   I-­‐1,	   whose	   activity	   is	   regulated	   by	   phosphorylation.217	   PKA-­‐mediated	  phosphorylation	  at	  T35	  converts	   I-­‐1	   into	  a	  potent	   inhibitor	  of	  PP1.218	  Conversely,	  PKCα-­‐mediated	   phosphorylation	   at	   S67	   and	   T75	   attenuates	   the	   inhibitory	   effect	   of	   I-­‐1	   on	  PP1.219,220	   This	   is	   illustrated	   in	   Figure	   8.1	   (panel	   B).	   Given	   that	   in	   neurons	   B56δ-­‐PP2A-­‐mediated	   dephosphorylation	   at	   T75	   increases	   PP1	   inhibition	   by	   DARPP-­‐32,114	   it	   is	  possible	   that	   in	   myocytes	   B56δ-­‐PP2A-­‐mediated	   	   dephosphorylation	   of	   I-­‐1	   at	   the	  equivalent	   residue	   (T75)	   and	   possibly	   also	   at	   S67	   also	   promotes	   I-­‐1-­‐mediated	   PP1	  inhibition.	   Thus,	   B56δ	   S573	   phosphorylation	   status,	   through	   its	   effects	   on	   B56δ-­‐PP2A	  activity	  and	  I-­‐1-­‐mediated	  PP1	  inhibition,	  might	  regulate	  the	  phosphorylation	  status	  of	  PP1	  substrate	  proteins	  indirectly.	  	  
One	   interesting	   observation	   that	   was	   reported	   in	   chapter	   7	   was	   the	   reduced	  phosphorylation	   of	   cMyBP-­‐C	   S282	   in	   ARVM	   expressing	   heterologous	   S573A	   B56δ.	   This	  might	   occur	   through	   reduced	   B56δ-­‐PP2A-­‐mediated	   dephosphorylation	   of	   I-­‐1	   and	  consequent	  increase	  in	  PP1	  activity,	  particularly	  since	  it	  has	  been	  reported	  that	  cMyBP-­‐C	  S282	  phosphorylation	  is	  impaired	  in	  transgenic	  mice	  with	  cardiac-­‐specific	  overexpression	  of	  inactive	  I-­‐1	  (i.e.	  I-­‐1	  constitutively	  phosphorylated	  at	  S67	  and	  T75).221	  	  








phosphorylation	   of	   PLM	   at	   S68	   would	   be	   increased	   in	   ARVM	   expressing	  WT	   B56δ	   and	  decreased	  in	  ARVM	  expressing	  S573A	  B56δ,	  through	  decreased	  or	  increased	  PP1	  activity,	  respectively	   (Figure	   8.1).	   In	   these	   future	   studies	   one	   might	   consider	   determining	   the	  phosphorylation	   of	   PP1	   substrates	   (including	   cMyBP-­‐C	   and	   PLM)	   in	   the	   absence	   and	  presence	   of	   the	   non-­‐selective	   AR	   agonist	   noradrenaline.	   This	   would	   activate	   PKCα	   and	  PKA	   simultaneously	   and	   thus	   would	   result	   in	   a	   more	   physiological	   regulation	   of	   I-­‐1	  phosphorylation.	  Depending	  on	  the	  outcome	  of	  such	  studies,	   it	  may	  then	  be	  necessary	  to	  also	  determine	  the	  phosphorylation	  of	  I-­‐1	  at	  its	  regulatory	  sites.	  Given	  that	  endogenous	  I-­‐1	  is	  not	  readily	  detected	  by	  immunoblot	  analysis	  in	  cardiac	  cells,223	  however,	  these	  studies	  would	  need	   to	  be	  performed	   in	  ARVM	  co-­‐transduced	  with	  an	  adenovirus	   that	   expresses	  the	  protein	  of	  interest.	  	  	  
A	  final	  important	  point	  to	  consider,	  is	  that	  both	  PP1	  and	  PP2A	  catalytic	  subunits	  can	  also	  dephosphorylate	  phosphorylated	  Ser	  and	  Thr	  residues	  that	  do	  not	  reside	  in	  PKA	  substrate	  motifs.	   Thus,	   future	  work	  would	   also	   involve	   investigating	   the	   phosphorylation	   of	   non-­‐PKA	  substrate	  phospho-­‐proteins	  in	  ARVM	  with	  heterologous	  expression	  of	  WT	  or	  S573A	  B56δ	   proteins,	   in	   the	   absence	   and	   presence	   of	   ISO	   stimulation.	   A	   possible	   approach	  towards	   this	   aim	   would	   be	   to	   use	   a	   selection	   of	   phospho-­‐motif	   antibodies	   and	  phosphorylation	   site-­‐specific	   antibodies,	   to	   determine	   the	   phosphorylation	   of	   unknown	  and	   specific	   substrates,	   respectively.	   Any	   phospho-­‐proteins	   that	   appear	   to	   be	   regulated	  through	  B56δ	  phosphorylation	  could	  then	  be	  identified	  by	  mass	  spectrometry	  approaches.	  	  
















Figure	  8.1	  Phospho-­‐regulation	  of	  DARPP-­‐32	  and	  I-­‐1	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